



Go Green, Go Online!
JDDonline.com

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years, these were printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

2012 SUBJECT INDEX

Letters after article titles refer to the following: **BC** = Brief Communication; **CR** = Case Reports; **CTR** = Clinical Trial Review; **NVR** = News, Views, and Reviews; **PP** = Pipeline Previews; **RR** = Resident Rounds; **RS** = Resident Spotlight

- A**
- Abbott:** HUMIRA® (adalimumab) for hidradenitis suppurativa, Phase 3 trials (PP), 669
- Absorica™:** FDA approval of CIP-ISOTRETINOIN (PP), 886
- Absorption,** percutaneous: regional variations in, overview, e48
- Acanthosis nigricans:** from repetitive same-site insulin injections (CR), e85
- Acitretin**
 -induced poliosis with concurrent alopecia (CR), 247
 elephantiassis nostras verrucosa treated by (CR), 402
- Acne**
 combination clindamycin phosphate 1.2% and BPO 2.5% treatment in adolescents with skin of color, 818
 combination clindamycin phosphate 1.2% and BPO 2.5% treatment in Fitzpatrick skin types, efficacy and tolerability study, 643
 combination salicylic acid and sandalwood oil acne treatment, open-label study, 1403
 current issues in topical treatment, s7 (June)
 customizing regimens for optimal outcomes (Editorial), s6 (June)
 home laser treatments (NVR), 666
 inflammatory: NicAzel dietary supplement management of, 1428
 novel approach to increasing patient outcomes and adherence to treatment regimens, s14 (June)
 in post-adolescent women: considerations for, 708
 real world strategies for customizing regimens for improved outcomes (CME), s4 (June)
 thinking outside the box (Editorial), 1400
- Acne fulminans:** skeletal and radiographic findings (RR), 114
- Acne keloidalis nuchae,** tumor stage: surgical excision and secondary intention healing treatment of (RR), 540
- Acne rosacea:** combination clindamycin phosphate 1.2% and tretinoin 0.025% treatment of, efficacy and safety study, 333
- Acne vulgaris**
 antioxidants in: focus on green tea and feverfew, s11 (September)
 combination adapalene-BPO and doxycycline followed by longer-term adapalene-BPO treatment of, efficacy and safety study, 174
 combination adapalene-BPO treatment, digital videography assessment of patient experiences, 919
 combination clindamycin phosphate 1.2% and BPO 2.5% gel treatment in Hispanics, post-hoc analysis, 455
 combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening treatment, efficacy and safety study, 748
 combination clindamycin phosphate 1.2% and tretinoin 0.025% treatment of, efficacy and safety study, 318
 comparative study of combination BPO 5% and clindamycin 1% and adapalene 0.1% for acne vulgaris treatment, 714
 comparative study of Fla. 855061 5 and tretinoin cream 0.025% treatments, safety and efficacy study, 737
 facial: dapsone 5% gel effects in female vs male patients, efficacy and tolerability study, 1417
 gevokizumab efficacy and safety in (CTR), 1136, 1523
 optimizing topical combination therapy for, review, 313
 oxidative stress and, 742
 RA-18C3 in, phase II study (CTR), 780
 therapeutic value of antioxidants in, 742
 treatment for pre-pubertal patients and those with IBD, s10 (June)
 in women: considerations for, 708
- Acrodermatitis enteropathica:** molecular basis for (RR), 1363
- Acropigmentation of Dohi:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Actavis Group:** generic equivalents of Clobex® shampoo and Clobex® topical lotion (PP), 423
- Actinic keratoses**
 chemopreventative effects of ALA PDT on multiple actinic keratoses with skin cancer history, 593
 combination blue light ALA-PDT treatment on upper extremities, phase 2 study, 1483
 diclofenac sodium 3% gel management of, efficacy and safety study, 600
 FDA approves Picato® (ingenol mebutate) gel for actinic keratoses, 547
 imiquimod 5% cream treatment of, observational study, 574
 paradigm shift in treatment: a comprehensive strategy (CME), 1462
- Active Naturals:** natural ingredients in atopic dermatitis, s7 (September)
- Acute bacterial infections:** tedizolid treatment of, Phase 3 trials (PP), 275
- Acyclovir:** comparative study of Dynamiclear™ and 5% Acyclovir cream for herpes skin lesions, 209
- Adalimumab (HUMIRA®)**
 efficacy and safety trial for hidradenitis suppurativa, s15 (May)
 Phase 3 trials for hidradenitis suppurativa (PP), 669
 psoriasis verrucosa treatment with (CR), e74
- Adapalene**
 combination adapalene-BPO acne vulgaris treatment, digital videography assess-
- ment of patient experiences, 919
 combination adapalene-BPO and doxycycline followed by longer-term adapalene-BPO acne vulgaris treatment, efficacy and safety study, 174
 comparative study of combination BPO 5% and clindamycin 1% and adapalene 0.1% for acne vulgaris treatment, 714
 comparative study of skin irritancy from combination clindamycin/tretinoin and benzoyl peroxide/adapalene, 1422
- Adenoma, sebaceous:** disease associations (RR), 1238
- Adherence to treatment**
 novel approach to increasing acne treatment regimens, s14 (June)
 tips for enhancing, s15 (June)
- Adnexal carcinoma, microcystic:** disease associations (RR), 1238
- Adoptive T-cell therapy:** for treatment of metastatic melanoma (NVR), 272
- Adrenergic urticaria:** adrenergic urticaria and rheumatoid arthritis with melanoma (CR), 409
- Advanced fluorescence technology:** Schamberg's disease treatment with (CR), 528
- ADVANTAGE™:** FDA clearance for (PP), 778
- Adverse reactions:** to chemotherapy agents (RR), 1120
- African-Americans**
 psoriasis in, caregivers' survey, 478
 Vogt-Koyanagi-Harada Disease in an African-American Female (RR) (CR), 1004
- Aging. See also Photo-aging**
 antioxidants in: focus on green tea and feverfew, s11 (September)
 home laser treatments for (NVR), 666
 NeoStrata® Skin Active antiaging effects, study results, 1447
 racial and ethnic differences in: implications for treatment with soft tissue fillers (CV), s30 (August)
- AiC316:** phase II trial clearance (PP), 1133
- AiCuris:** AiC316 phase II trial clearance (PP), 1133
- AIN457 (secukinumab):** new Novartis phase 2 data (PP), 1379
- Albright hereditary osteodystrophy**
 molecular basis for (RR), 1361
 skeletal and radiographic findings (RR), 114
- Alefcept:** combination alefcept and nbUVB phototherapy for psoriasis, efficacy study, 929
- Alexandrite laser**
 comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser, for axillary hair removal, 185
 long-pulse: benign pigmented lesion treatment with, 1327
- Alezzandri syndrome:** gene (mode of inheritance) and clinical manifestations (RR), 998

Alkaptonuria
histologic characteristics (RR), 1503
skeletal and radiographic findings (RR), 114

Allergan: Botox manufacturing expansion in Ireland (PP), 423

Allergens: contact allergens relevant to dermatitis in special locations (RR), 657

Allergic contact dermatitis: apremilast in, safety and efficacy study, 341

Allergy to topical steroids, s9 (December)

Alma Lasers: FDA approval of Pixel RF (PP), 1521

Alopecia
acitretin-induced poliosis with (CR), 247
cicatricial: trichoscopy of, prospective study, 753

Alopecia areata: Vytorin (simvastatin and ezetimibe) treatment of, pilot study (CTR), 780

Alpharma: clotrimazole and betamethasone dipropionate topical cream launch (PP), 423

Altabax ointment: for secondarily infected atopic dermatitis, safety and efficacy study (CTR), 276

Aminocaproic acid: combination topical aminocaproic acid and Vanicream rosacea treatment, single-site study, 888

Aminolevulinic acid with photodynamic therapy (ALA PDT)
chemopreventative effects on multiple actinic keratoses with skin cancer history, 593
combination blue light ALA-PDT treatment of actinic keratoses on upper extremities, phase 2 study, 1483

Amyloidosis
association with monoclonal gammopathy (RR), 530
of dermatologic significance (RR), 250

AN2728: Anacor Pharmaceuticals announces positive preliminary results (PP), 275

AN2898: Anacor Pharmaceuticals announces positive preliminary results (PP), 275

Anacor Pharmaceuticals
positive preliminary results (PP), 275
tavorole for onychomycosis Phase 3 trials (PP), 275

Anakinra/kineret: for severe atopic dermatitis, pilot study (CTR), 671

Anatabloc® face cream: Star Scientific's Rock Creek Pharmaceuticals, Inc launches (PP), 1521

Anemia, Fanconi: skeletal and radiographic findings (RR), 115

Anesthesia
FDA approval of Pliaglis as topical anesthetic peel (PP), 1521
virtually painless local anesthesia: diluted lidocaine for subcutaneous infiltration, e39

Anesthetic peels
FDA approval of Pliaglis as topical anesthetic peel (PP), 1521

Anti-aging: comparative trial of non-prescription tri-retinol 1.1% vs prescription tretinoin 0.025% for, 64

Anti-PD-1 immunotherapy: BMS-936558: interim results, Phase 1 trial (PP), 886

Antibiotics
combination antibiotic and corticosteroid cream eczema treatment, 861
combination therapy for acne vulgaris, optimizing, 313
oral: most commonly prescribed for impetigo, 489
triple antibiotic ointment nasal *S aureus* clearance, 1490

Antidepressants: successful treatment of patients previously labeled as having "delusions of parasitosis" with (CR), 1506

Antioxidants
in acne vulgaris and aging: focus on green tea and feverfew, s11 (September)
systemic, and skin health, e1
therapeutic value in acne vulgaris, 742

Antiphospholipid antibody syndrome secondary to trimethoprim/sulfamethoxazole (CR), 1117

Antisense Pharma GmbH: FDA Orphan Drug designation for trabectedin for malignant melanoma (PP), 1134

Antivirals: novel topical antiviral NB-001 cold sore treatment, safety and efficacy study, 970

Apert syndrome: skeletal and radiographic findings (RR), 114

Apocrine neoplasms: disease associations (RR), 1237

Apremilast
for discoid lupus erythematosus, phase 2 study, 1224
safety and efficacy in allergic contact or atopic dermatitis, phase 2 study, 341

Aptalis Pharma: agreement to market RECTIV™ in the U.S. (PP), 547

Aqua Pharmaceuticals: acquisition of FLUOROPLEX® (PP), 423

Arthritis
psoriatic: ustekinumab treatment review, 160
rheumatoid: adrenergic urticaria and rheumatoid arthritis with melanoma (CR), 409

Arthrogyposis-renal dysfunction-cholestasis: molecular basis for (RR), 1362

L-Ascorbic acid serum: topical: efficacy and safety on photo-aged skin study, 51

Atopic dermatitis
anakinra/kineret treatment of, pilot study (CTR), 671
apremilast in, safety and efficacy study, 341
childhood: comparative study of 5% dexpantenol in water-in-oil and 1% hydrocortisone ointment treatment, 366
childhood: risk factors for: truth or fiction (NVR), 126
childhood: severe: management of, 1158
colloidal oatmeal formulations as adjunct treatments for, 804
facial
clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
HL-009 liposomal gel in adult patients with, safety and efficacy study (CTR), 1012
hydrogel vehicle treatment of: transepidermal water loss (TEWL) and corneometry with, 181
infected: retapamulin 1% ointment treatment of, pilot study, 858
natural ingredients in, s7 (September)
secondarily infected: Altabax ointment treatment of, safety and efficacy study (CTR), 276
supplement use in, evidence for (NVR), 1245
T helper cell subsets in development of, 1174
vitamin D supplementation treatment of, clinical trial study, 327

Atopic eczema: combination antibiotic and corticosteroid cream treatment of, 861

Atralin® gel for tretinoin penetration (PP), 130

Attractiveness: feelings of, improvement by cheek augmentation, 1077

Autoimmune mucocutaneous blistering skin disease: rituximab treatment of, literature review, 622

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: gene (mode of inheritance) and clinical manifestations (RR), 998

Axillary hair removal: comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser for, 185

Axillary hyperhidrosis, focal: Nd:YAG nm laser hair reduction treatment for, study, 59

Azelaic acid: comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment (CTR), 1136, 1524

Azficel-T (LAVIV™): trial data (PP), 778

Azilect (rasagiline): livedo reticularis associated with (CR), 764

B

Back acne: short-contact BP 9.8% emollient foam treatment of *P acnes*, comparative study, 830

Bacterial infections, acute: tedizolid treatment of, Phase 3 trials (PP), 275

Bannayan-Riley-Ruvalcaba syndrome: gene (mode of inheritance) and clinical manifestations (RR), 997

Bannayan Riley Ruvalcaba syndrome: molecular basis for (RR), 1361

Barley-produced, synthetic, human-like EGF serum for photodamage and aging in facial skin, efficacy study, 613

Basal cell carcinoma
advanced: FDA approves Erivedge (vismodegib) for (PP), 546
electronic brachytherapy for NMSC study (CTR), 671
infiximab (Remicade) and increased incidence of (CR), 655
nevroid syndrome: urticaria after methyl aminolevulinic photodynamic therapy in (CR), 1364
nonmelanoma: electronic brachytherapy for NMSC study (CTR), 671
in skin of color, 484
vismodegib adjuvant to surgery for basal cell carcinoma tumors, pilot study (CTR), 1012

Beautiful Oenobiol: Sanofi, Coca-Cola join efforts on (PP), 1521

Beauty drinks: Sanofi, Coca-Cola join efforts on (PP), 1521

Beckwith-Wiedemann syndrome: skeletal and radiographic findings (RR), 114

Behcet disease: skeletal and radiographic findings (RR), 114

BELOTERO Balance® for facial wrinkles and folds (PP), 131

Belotero Basic: retrospective review for facial treatments, 1032

Benzoyl peroxide (BP or BPO)
combination adapalene-BPO acne vulgaris treatment, digital videography assessment of patient experiences, 919
combination adapalene-BPO and doxycycline followed by longer-term adapalene-BPO acne vulgaris treatment, efficacy and safety study, 174
combination clindamycin/BPO therapy acne vulgaris therapy, optimizing, 313
combination clindamycin phosphate 1.2% and BPO 2.5% acne treatment in adolescents with skin of color, 818
combination clindamycin phosphate 1.2% and BPO 2.5% acne treatment in Fitzpatrick skin types, efficacy and tolerability study, 643
combination clindamycin phosphate 1.2% and BPO 2.5% acne vulgaris treatment in Hispanics, post-hoc analysis, 455
combination clindamycin phosphate 1.2% and BPO 2.5% benefits: gender differences in, 1440
combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening acne vulgaris treatment, efficacy and safety study, 748
comparative study of combination BPO 5% and clindamycin 1% and adapalene 0.1% for acne vulgaris treatment, 714
comparative study of skin irritancy from combination clindamycin/tretinoin and benzoyl peroxide/adapalene, 1422
FDA approval and launch of clindamycin phosphate and BPO 1.2%/5% gel (PP), 1009
short-contact 9.8% emollient foam treatment of *P acnes* on the back, comparative study, 830

Beta-adrenergic antagonists: treatment of infantile hemangiomas with, review, 826

Betamethasone dipropionate (BMD)

- clotrimazole & BMD topical cream launch (PP), 423
- combination calcipotriol 0.005% and betamethasone dipropionate 0.05% vitiligo treatment, efficacy and safety study, e52
- BI 2536:** antitumor activities against melanoma, in vitro, 587
- Bimatoprost, topical:** for eyebrow hypotrichosis (CR), 106
- BIOEFFECT EGF Serum** for photodamage and aging in facial skin, efficacy study, 613
- Biologic therapy** for psoriasis considerations for when to initiate, s11 (May) PSOLAR study, 1210
- Biomimetic electrical signaling,** topical: application to photo-aging, 30
- Bionect®:** agreement with DARA (PP), 668
- Birt-Hogg-Dubé syndrome:** histologic characteristics (RR), 1503
- Blepharospasm, essential:** botulinum toxin treatment of: effects of dietary zinc and phytase supplementation on, 507
- Blood pressure, high:** white coat hypertension in Mohs micrographic surgery, e18
- Bloom syndrome:** molecular basis for (RR), 1361
- Blue light:** combination blue light ALA-PDT treatment of actinic keratoses on upper extremities, phase 2 study, 1483
- Blunt-tipped cannulas**
- an ethical duty? (Editorial), s42 (August)
 - comparative study of injections of filler with microcannulas and hypodermic needles, 1098
 - a consensus panel assessment and recommendations, s33 (August)
 - faculty usage, quick polls, s43 (August), s44 (August)
 - filler injections with blunt-tip microcannula, 1098
 - a personal perspective (Editorial), s41 (August)
 - for soft tissue fillers (BC), 70
 - for soft tissue fillers in specific regions (Editorial), s40 (August)
- BMS-936558:** interim results, Phase 1 trial (PP), 886
- Bocouture®/Xeomin®** (incobotulinumtoxinA): comparative study of incobotulinumtoxinA and onabotulinumtoxinA, meta-analysis, 731
- Body moisturizers:** comparative studies of stratum corneum integrity benefits, 22
- Body plaque psoriasis:** FDA approval of Taclonex® topical suspension, 0.005%/0.064% for (PP), 1521
- Botanical products:** green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications, e55
- Botox®/Vistabel®** (onabotulinumtoxinA)
- Allergan plans manufacturing expansion in Ireland (PP), 423
 - comparative study of incobotulinumtoxinA and onabotulinumtoxinA, meta-analysis, 731
- Botulinum toxin**
- comparative study of incobotulinumtoxinA and onabotulinumtoxinA, meta-analysis, 731
 - comparative study of preparations in treatment of hyperdynamic forehead lines, 216
 - effects of dietary zinc and phytase supplementation on treatment with, 507
 - efficacy and safety study for moderate-to-severe lateral canthal line treatment, 38
 - muscle mass consideration in glabellar line treatment with, 1041
- Bovine-derived collagen/elastin matrix:** reconstruction of full-thickness defects with, challenging cases and post-burn facial reconstruction (SC), 866
- Breast cancer, paclitaxel-treated:** paclitaxel-associated subungual pyogenic granuloma in (CR), 262
- Brief Communications (BC):** use of blunt-tipped cannulas for soft tissue fillers (BC), 70
- Brightening:** comparative study of SMA-432 and 4% hydroquinone for, efficacy and safety of, 1478
- Brittle nails:** FDA approval of Nuvail for (PP), 1370
- Brooke-Spiegler syndrome:** histologic characteristics (RR), 1503
- Bullous pemphigoid** associated with renal cell carcinoma and invasive squamous cell carcinoma (CR), 234
- Buschke-Ollendorff syndrome**
- histologic characteristics (RR), 1504
 - molecular basis for (RR), 1363
 - skeletal and radiographic findings (RR), 114
- Butaconazole nitrate 2% vaginal cream:** FDA approval (PP), 886
- Buttocks:** extramedullary plasmacytoma presenting as asymptomatic nodules on buttocks and thighs (RR), 1244
- ## C
- Café au lait macules** (CALMs): multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812
- Caffeine:** protective effects against acute ROS-induced necrosis, 1342
- Calcipotriene:** FDA approves first generic version of Dovonex Cream (PP), 1134
- Calcipotriol:** combination calcipotriol 0.005% and betamethasone dipropionate 0.05% vitiligo treatment, efficacy and safety study, e52
- Calcitriol:** combination 308 nm excimer laser, clobetasol spray, and calcitriol ointment for treatment of psoriasis and long-term maintenance (CR), 994
- Canada:** skin product approved for diabetic foot ulcers in (PP), 1249
- Cancer.** See also **Skin cancer;** specific types
- ingenol mebutate: potential for further development of cancer immunotherapy, 1156
 - ingenol mebutate-induced cell death patterns in, 1181
- Cannulas, blunt-tipped**
- an ethical duty? (Editorial), s42 (August)
 - comparative study of injections of filler with microcannulas and hypodermic needles, 1098
 - a consensus panel assessment and recommendations, s33 (August)
 - faculty usage, quick polls, s43 (August), s44 (August)
 - filler injections with, 1098
 - a personal perspective (Editorial), s41 (August)
 - for soft tissue fillers, 70
 - for soft tissue fillers in specific regions (Editorial), s40 (August)
- Canthal lines**
- Botulinum Toxin Type A Topical Gel for: efficacy and safety study, 38
 - injectable hyaluronic acid with 0.3% lidocaine hydrochloride for (CTR), 134
- Cantharidin:** combination TCA 50% and cantharidin 0.7% for response to SADBE, 1228
- Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia** (CR), 769
- Carbon dioxide (CO₂) laser**
- combination radiofrequency and CO₂ laser treatment of periorbital syringoma (CR), 879
 - comparative study of ultrapulse-mode and superpulse-mode fractionated CO₂ laser photoaged skin treatment, 1310
 - novel superficial and deep fractional system in treatment of patients with skin of color, safety and efficacy of, 1331
 - pathergic response to fractional CO₂ (CR), 1122
- Cardio-facio-cutaneous syndrome:** molecular basis for (RR), 1362
- Cardiovascular disease:** psoriasis and its comorbidities, s7 (May)
- Cardium Therapeutics:** FDA-cleared Excellagen® (PP), 778
- Carney complex**
- gene (mode of inheritance) and clinical manifestations (RR), 997
 - histologic characteristics (RR), 1503
 - molecular basis for (RR), 1361
- Cartilage batten grafts,** nonanatomic free: with second intention healing: for distal nose defects, 46
- Cartilage-hair hypoplasia syndrome:** skeletal and radiographic findings (RR), 114
- Case reports (CR)**
- acanthosis nigricans resulting from repetitive same-site insulin injections, e85
 - adalimumab treatment of psoriasis verrucosa, e74
 - adrenergic urticaria and rheumatoid arthritis with melanoma
 - medical management of, 409
 - anti-TNF- α agent treatment of generalized vitiligo, 534
 - antiphospholipid antibody syndrome secondary to trimethoprim/sulfamethoxazole, 1117
 - bimatoprost treatment of eyebrow hypotrichosis, 106
 - bullous pemphigoid associated with renal cell carcinoma and invasive squamous cell carcinoma, 234
 - capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia, 769
 - combination therapy for lichen striatus in children, case series and review, 872
 - drug eruptions, challenging, 1494
 - drug-induced pyogenic granulomas adjacent to and beneath the nail, 262
 - elephantiasis nostras verrucosa treated by acitretin, 402
 - facial melasma treatment with Lumixyl Topical Brightening System, 660
 - finasteride and fertility: case report and literature review, 1511
 - hepatitis B in ustekinumab-treated psoriasis, 1498
 - hypopigmented cutaneous sarcoidosis responsive to minocycline, 385
 - infliximab (Remicade) and increased incidence of basal cell carcinoma, 655
 - leprosy-like illness with *Mycobacterium lepromatosis*, in patient from Ontario, Canada, 229
 - livedo reticularis associated with rasagiline (Azilect), 764
 - long-term etanercept for severe generalized psoriasis in HIV infection, case study, 413
 - lupus-like reaction to subcutaneous interferon- α at injection sites, 393
 - multifocal, fixed-drug eruption masquerading as recurrent erythema multiforme, 244
 - myxed neurothekeoma of the nose, 252
 - paclitaxel-associated subungual pyogenic granuloma in paclitaxel-treated breast cancer, 262
 - pathergic response to fractional CO₂, 1122
 - pedunculated melanoma (RR), 269
 - periorbital syringoma treated with radiofrequency and carbon dioxide (CO₂) laser, 879
 - pseudoeplithiomatous hyperplasia and transepidermal elimination in lepromatous leprosy: does T-cell plasticity play a role?, 1232
 - Schamberg's disease treatment with advanced fluorescence technology, 528
 - successful treatment of patients previously labeled as having "delusions of parasitosis" with antidepressant therapy, 1506
 - TNF- α inhibitor therapy for *M. tuberculosis* infection effects on chronic psoriasis, 119
 - treatment of psoriasis and long-term maintenance with 308 nm excimer laser, clobetasol spray, and calcitriol ointment, 994

- ulcerated necrobiosis lipoidica treatment with IVIG and methylprednisolone, 256
- urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome, 1364
- ustekinumab treatment of plaque psoriasis in a patient with Down syndrome, 998
- ustekinumab treatment of severe psoriasis during pregnancy, 1240
- in vivo reflectance confocal microscopy features of discoid lupus erythematosus, 1111
- Vogt-Koyanagi-Harada Disease in an African-American Female (RR), 1004
- vulvar lesions, persistent erythematous, 110
- Case studies:** long-term etanercept for severe generalized psoriasis in HIV infection (CR), 413
- Case vignettes (CV)**
- fillers and the "three curves of youth," s9 (August)
- racial and ethnic differences in skin aging: implications for treatment with soft tissue fillers, s30 (August)
- Tower Technique and Vertical Supraperiosteal Depot Technique: novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation, s45 (August)
- CD07805/47 gel:** comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment (CTR), 1136, 1524
- Cell-based therapy,** spray-on: for leg ulcers (PP), 1133
- Cetaphil® Dermacontrol Moisturizer (CDM):** adjunctive use with topical tretinoin 0.05%, split-face study, 1104
- Chediak-Higashi syndrome**
- gene (mode of inheritance) and clinical manifestations (RR), 998
- molecular basis for (RR), 1362
- Cheek augmentation**
- with Emervel® fillers: efficacy, patient satisfaction, and safety of, s9 (January)
- feelings of facial attractiveness improved by, 1077
- Chemicals,** simple, in animals and man: mechanisms of contact sensitivity, 1166
- Chemotherapy:** adverse cutaneous reactions to chemotherapy agents (RR), 1120
- CHILD syndrome**
- histologic characteristics (RR), 1504
- molecular basis for (RR), 1362
- skeletal and radiographic findings (RR), 115
- Childhood atopic dermatitis**
- comparative study of 5% dexpantenol in water-in-oil and 1% hydrocortisone ointment treatment, 366
- risk factors for: truth or fiction (NVR), 126
- severe: management of, 1158
- Children**
- acne treatment for pre-pubertal patients, s10 (June)
- combination therapy for lichen striatus treatment, case series and review (CR), 872
- molluscum contagiosum in: combination TTO and iodine treatment of, 349
- Chronic granulomatous disease:** skeletal and radiographic findings (RR), 114
- Chronic plaque psoriasis**
- CP-690,550 treatment, efficacy and safety study (CTR), 276
- secukinumab 300 mg s.c. treatment, long-term effects study (CTR), 1251
- secukinumab 300 mg s.c. treatment, phase II study (CTR), 1382
- secukinumab treatment, safety and efficacy of (CTR), 424
- Chronic ulcers:** when to consider malignancy? (NVR), 1006
- Cicatricial alopecia:** trichoscopy of, prospective study, 753
- CIP-ISOTRETINOIN:** FDA approval (PP), 886
- Cipher Pharmaceuticals Inc.:** FDA approval of CIP-ISOTRETINOIN (PP), 886
- Citrullinemia:** molecular basis for (RR), 1363
- Clindamycin**
- antimicrobial effects on Propionibacterium acnes, 1434
- combination clindamycin/BPO acne vulgaris therapy, optimizing, 313
- combination clindamycin phosphate 1.2% and BPO 2.5% acne treatment in adolescents with skin of color, 818
- combination clindamycin phosphate 1.2% and BPO 2.5% acne treatment in Fitzpatrick skin types, efficacy and tolerability study, 643
- combination clindamycin phosphate 1.2% and BPO 2.5% acne vulgaris treatment in Hispanics, post-hoc analysis, 455
- combination clindamycin phosphate 1.2% and BPO 2.5% benefits: gender differences in, 1440
- combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening acne vulgaris treatment, efficacy and safety study, 748
- combination clindamycin phosphate 1.2% and tretinoin 0.025% acne rosacea treatment, efficacy and safety study, 333
- combination clindamycin phosphate 1.2% and tretinoin 0.025% acne vulgaris treatment, efficacy and safety study, 318
- combination clindamycin phosphate 1.2% and tretinoin 0.025% antimicrobial effects, 1434
- combination clindamycin phosphate 1.2% and tretinoin 0.025% rosacea treatment: summary of a placebo-controlled, double-blind trial, 1410
- comparative study of combination BPO 5% and clindamycin 1% and adapalene 0.1% for acne vulgaris treatment, 714
- comparative study of skin irritation from combination clindamycin/tretinoin and benzoyl peroxide/adapalene, 1422
- FDA approval and launch of clindamycin phosphate and BPO 1.2%/5% gel (PP), 1009
- Clinical Trial Reviews (CTR)**
- CNTO 1959 treatment of plaque-type psoriasis, 548
- combination topical aminocaproic acid and Vanicream rosacea treatment, 888
- comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment of periorbital wrinkles, pilot trial, 781, 1013
- comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment, 1136, 1524
- comparative study of LY2439821 and etanercept plaque psoriasis treatment, 1251, 1382
- comparative study of pulsed dye laser and 1064-nm Nd:YAG laser treatment of facial redness, pilot study, 888
- comparative study of sunitinib and dacarbazine treatment of metastatic uveal melanoma, 548
- effectiveness study of MIST Therapy after cosmetic surgery procedures of the face and body, 135
- efficacy, safety, and patient satisfaction of injectable hyaluronic acid with 0.3% lidocaine hydrochloride for superficial, vertical perioral lines and superficial, horizontal, lateral canthal lines, 135
- electronic brachytherapy for NMSC, 671
- etanercept as sole treatment for grade I acute graft-versus-host disease, 276
- investigator-initiated study of retapamulin 1% ointment treatment of hand and foot eczema, 889
- laser treatment of melasma, 134
- long-term effects study of secukinumab 300 mg s.c. chronic plaque-type psoriasis treatment, 1251
- 1320 nm Nd:YAG laser for improving onychomycosis appearance, 548
- delineation of non-melanoma skin cancers, 672
- Phase 3 study of CP-690,550 plaque psoriasis treatment effects, 889
- phase I/II study of IL-12 modified TIL therapy of metastatic melanoma, 1382
- phase II study of RA-18C3 in moderate to severe acne vulgaris, 780
- phase II study of secukinumab 300 mg s.c. chronic plaque-type psoriasis treatment, 1382
- pilot study of anakinra/kineret for severe atopic dermatitis, 671
- pilot study of vismodegib as adjuvant to surgery for basal cell carcinoma tumors, 1012
- pilot study of Vytorin (simvastatin and ezetimibe) alopecia areata treatment, 780
- prospective study of Pellevé™ for neck wrinkles, 135
- prospective study of topical timolol 0.5% for proliferating infantile hemangiomas, 424
- safety, tolerability, and efficacy of PD-0360324 in active cutaneous lupus erythematosus, 424, 1136
- safety and efficacy of Altanax ointment for secondarily infected atopic dermatitis, 276
- safety and efficacy of CNTO 1959 for plaque-type psoriasis, 425
- safety and efficacy of CP-690,550 for chronic plaque psoriasis, 276
- safety and efficacy of gevokizumab for acne vulgaris, 1136, 1523
- safety and efficacy of HL-009 liposomal gel in adult patients with mild to moderate atopic dermatitis, 1012
- safety and efficacy of IL-12 modified tumor white blood cells treatment of metastatic melanoma, 1251
- safety and efficacy of incobotulinumtoxinA to cheek for rosacea, 1523
- safety and efficacy of Luliconazole Solution 10% in distal subungual onychomycosis of the toenails, 1013
- safety and efficacy of secukinumab for chronic plaque-type psoriasis, 424
- safety and tolerability study of SHP 141 effects on cutaneous T-cell lymphoma, 1252, 1383
- sirolimus treatment of pemphigus, 277
- tretinoin prevention of EGFRi-associated dermatologic toxicities, 780
- V-Raser diode laser system treatment of onychomycosis, 1137
- Clobetasol**
- clobetasol propionate 0.05% spray: effects on health-related QOL in patients with plaque psoriasis, 1348
- clobetasol propionate 0.05% spray: effects on signs and symptoms of plaque psoriasis, efficacy and safety study, 1455
- combination 308 nm excimer laser, clobetasol spray, and calcitriol ointment for treatment of psoriasis and long-term maintenance (CR), 994
- Clobex®:** generic equivalents of shampoo and topical lotion shampoo and Clobex® topical lotion, 423
- Clocortolone pivalate:** efficacy and safety of 0.1% cream treatment of inflammatory facial dermatoses, 1194
- Clotrimazole:** combination clotrimazole & BMD topical cream launch (PP), 423
- CNTO 1959**
- for plaque-type psoriasis: safety and efficacy study (CTR), 425
- for plaque-type psoriasis: treatment study (CTR), 548
- Coca-Cola:** Sanofi, Coca-Cola join efforts on beauty drinks (PP), 1521
- Cockayne genodermatosis**
- molecular basis for (RR), 1361
- skeletal and radiographic findings (RR), 114

- Coffin-Siris genodermatosis:** skeletal and radiographic findings (RR), 114
- Cold sores:** novel topical antiviral NB-001 treatment, safety and efficacy study, 970
- Colloidal oatmeal formulations:** as adjunct treatments in atopic dermatitis, 804
Complementary and alternative medicine. *See* **Natural ingredients**
- Complex forehead defects:** novel reconstructive technique and review of available methods for, 759
- Composite grafts:** nasal Ala reconstruction with crus helix composite graft: stepladder approach (SC), 376
- Congenital erythropoietic porphyria:** skeletal and radiographic findings (RR), 114
- Conradi-Hunemann syndrome**
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 114
- Consensus Documents:** blunt-tipped microcannulas for the injection of soft tissue fillers: a consensus panel assessment and recommendations, s33 (August)
- Contact allergens:** relevant to dermatitis in special locations (RR), 657
- Contact dermatitis**
allergens relevant to dermatitis in special locations (RR), 657
allergic: apremilast in, safety and efficacy study, 341
facial: clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
- Contact sensitivity**
mechanisms of, 1166
microRNA 150 in humans and murine contact sensitivity (letter to the editor), 1152
- Continuing medical education (CME)**
identifying natural ingredients and their use in skin care, s4 (September)
the new face of fillers: a multi-specialty CME initiative (Part II of II), s5 (August)
the new face of fillers: a multi-specialty CME initiative: Supplement Part II of II (Editorial), s8 (August)
paradigm shift in treating actinic keratosis: comprehensive strategy, 1462
real world strategies for customizing acne regimens for improved outcomes, s4 (June)
- Contractubex® gel:** immunohistochemical and ultrastructural effects on scar formation study, 74
- Cooks syndrome:** skeletal and radiographic findings (RR), 115
- Copper sulfate:** comparative study of Dynamisclear™ and 5% Acyclovir cream for, 209
- Cornelia de Lange syndrome:** skeletal and radiographic findings (RR), 115
- Corneometry:** with hydrogel vehicle in atopic dermatitis treatment, 181
- Corticosteroids**
allergy to topical steroids, s9 (December)
combination antibiotic and corticosteroid cream eczema treatment, 861
practical aspects of topical corticosteroid selection (Editorial), s3 (December)
vehicle formulations, compound selection, and methods of application, s5 (December)
- Cosmetic niacinamide/glycerin body moisturizers:** comparative studies of stratum corneum integrity benefits, 22
- Costello syndrome:** molecular basis for (RR), 1362
- Cowden syndrome**
histologic characteristics (RR), 1503
molecular basis for (RR), 1361
- CP-690,550**
for chronic plaque psoriasis, efficacy and safety study (CTR), 276
plaque psoriasis treatment effects, Phase 3 study (CTR), 889
- Cronkrite-Canada disease:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Crowdsourcing in eczema research:** a novel method of data collection (letter to the editor), 1153
- Crus helix composite graft:** nasal Ala reconstruction with: stepladder approach (SC), 376
- Cryoglobulemia:** association with monoclonal gammopathy (RR), 530
- Cultural competence:** with ethnic skin, 460
- Cutaneous inflammation:** improved co-culture model results, 834
- Cutaneous lupus erythematosus (CLE), active:** safety, tolerability, and efficacy study of PD-0360324 in (CTR), 424, 1136
- Cutaneous reactions**
challenging drug eruptions (CR), 1494
injection-site, to enfuvirtide, e35
to proton pump inhibitors, case-control study, e43
- Cutaneous T-cell lymphoma:** SHP 141 effects on, safety and tolerability study (CTR), 1252, 1383
- Cutis marmorata telangiectatica, congenital:** skeletal and radiographic findings (RR), 115
- Cyclosporine:** use of, in dermatology, 979
- Cylindroma:** disease associations (RR), 1238
- D**
- Dacarbazine:** comparative study of sunitinib and dacarbazine treatment of metastatic uveal melanoma (CTR), 548
- Dapsone 5% gel:** effects in female vs male patients with facial acne vulgaris, efficacy and tolerability study, 1417
- DARA BioSciences, Inc.:** agreement with Innocutis for Bionect® (PP), 668
- Data collection:** crowdsourcing in eczema research: a novel method of data collection (letter to the editor), 1153
- Deficiency of interleukin 1-receptor agonist (DIRA):** skeletal and radiographic findings (RR), 115
- Delusions of parasitosis**
approach to (NVR), 543
successful treatment of patients previously labeled as having (CR), 1506
- DeoxyArbutin (dA):** effects on tyrosinase and melanization, studies, e28
- DeoxyFuran (dF):** effects on tyrosinase and melanization, studies, e28
- Depression:** psoriasis and its comorbidities, s8 (May)
- Dermablend:** introduction of Skin Perfector Pigment Correcting Primer (PP), 1009
- Dermabrasion**
microdermabrasion: molecular mechanisms unraveled, e5, e10
upper lip: new simple, safe, and easy solution for (SC), 649
- Dermagraft:** approval for diabetic foot ulcers in Canada (PP), 1249
- Dermal fillers. *See also* Fillers**
basic science: adverse effects, 1069
basic science: background and mechanisms of action, 1059
safety of, 1053
- Dermatitis**
atopic (*See* **Atopic dermatitis**)
contact (*See* **Contact dermatitis**)
radiation dermatitis: current perspectives and future directions (NVR), 1127
seborrheic, of the scalp: naftifine 1% gel treatment of, pilot study, 514
- Dermatoheliosis:** tretinoin cream 0.02% safety and efficacy pilot study for reduction of, 83
- Dermatologic syndromes. *See also* specific syndromes**
histologic characteristics (RR), 1503
- Dermatological disorders. *See also* specific disorders**
associated with monoclonal gammopathy (RR), 530
skeletal and radiographic findings (RR), 114
top conditions in patients of color, nationally representative data, 466
- Dermatological infectious disease. *See also* specific diseases**
nanotechnology and diagnosis of, 846
- Dermatology education. *See* Resident Rounds (RR); Training programs**
- Dermatopathia pigmentosa reticularis:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Dermatopathology bodies:** review (RR), 876
- Dermatosis**
perforating, with primary sclerosing cholangitis, case review (RR), 881
pustular, subcorneal: association with monoclonal gammopathy (RR), 532
- Dermatosparaxis:** molecular basis for (RR), 1362
- Derموchondrocorneal dystrophy (François syndrome):** skeletal and radiographic findings (RR), 115
- Desmoplastic trichoepithelioma:** disease associations (RR), 1237
- Desonide:** combination desonide 0.05% and tazartone 0.05% lichen striatus treatment in children, case series and review (CR), 872
- Dexpantenol (vitamin B5):** comparative study of 5% dexpantenol in water-in-oil and 1% hydrocortisone ointment for childhood atopic dermatitis treatment, 366
- Diabetes mellitus:** psoriasis and its comorbidities, s9 (May)
- Diabetic foot ulcers:** skin product approved for, in Canada (PP), 1249
- Diclofenac sodium 3% gel (Solaraze®):** for actinic keratosis management, efficacy and safety study, 600
- Dietary supplements**
evidence for supplement use in atopic dermatitis (NVR), 1245
novel NicAzel: inflammatory acne management with, 1428
- Differin Gel:** FDA approves pump dispenser for (PP), 668
- Diflucortolone valerate:** combination isoconazole nitrate and diflucortolone valerate tinea inguinalis treatment, retrospective study, e70
- Digital videography:** assessment of combination adapalene-BPO acne vulgaris treatment patient experiences, 919
- Diode laser treatment:** V-Raser system, onychomycosis treatment study (CTR), 1137
- Discoid lupus erythematosus**
apremilast for, phase 2 study, 1224
in vivo reflectance confocal microscopy features of (CR), 1111
- Distal nose defects**
nonanatomic free cartilage batten grafting with second intention healing for, 46
reconstruction with hatchet and bilobed flaps, 99
- Dovonex Cream:** FDA approves first generic version of Dovonex Cream (PP), 1134
- Dowling-Degos disease:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Down syndrome**
histologic characteristics (RR), 1504
skeletal and radiographic findings (RR), 115
ustekinumab treatment of plaque psoriasis in a patient with (CR), 998
- Doxycycline**
combination adapalene-BPO and doxycycline followed by longer-term adapalene-BPO acne vulgaris treatment, efficacy and safety study, 174
modified-release capsules for papulopustular rosacea treatment, effectiveness and safety study, 703

once-daily capsules for rosacea monotherapy in patients with skin of color, effectiveness and safety study, 1219
safety studies (letter to the editor), 20

Drug absorption, percutaneous: regional variations in, overview, e48

Drug eruptions: challenging (CR), 1494

Drug-induced pyogenic granulomas: adjacent to and beneath the nail (CR), 262

Duke Dermatology residency training program (RR), 1115

Dynamiclear™: comparative study of Dynamiclear™ and 5% Acyclovir cream for herpes skin lesions, 209

Dyskeratosis congenita: molecular basis for (RR), 1361

E

Eccrine neoplasms: disease associations (RR), 1237

Eczema

combination antibiotic and corticosteroid cream treatment of, 861

crowdsourcing in eczema research: a novel method of data collection (letter to the editor), 1153

nickel sulfate-induced methylprednisolone aceponate 0.1% and (PP), 1379

retapamulin 1% ointment treatment of hand and foot eczema, investigator-initiated study (CTR), 889

Editorials

acne & rosacea: thinking outside the box, 1400
blunt-tipped microcannulas for filler injection: an ethical duty?, s42 (August)

customizing acne regimens for optimal outcomes, s6 (June)

Emerve[®] fillers: full-face rejuvenation with a range of customized hyaluronic acid fillers, s4 (January)

introduction, s6 (September)

JDD: celebrating 10 years of publishing excellence, 17, 155, 297, 445, 569, 681, 799, 898, 1028, 1150, 1268, 1398

Letter from the Guest Editor, s4 (May)

melanoma-detecting technologies and standard of care, 1270

In Memoriam: Murray Gruber MD, 453

Message from the Guest Editor, 686, 803, 906, 1030

Mycobacterium lepromatosis: emerging strain or species?, 158

the new face of fillers: a multi-specialty CME initiative: Supplement Part II of II, s8 (August)

the new face of fillers: integrating evidence, experience and a little imagination at the next frontier, 20

practical aspects of topical corticosteroid selection, s3 (December)

skin cancer: prevention and latest treatments, 572
study of skin of color, 448

training in dermatologic surgery, 800

utilizing blunt-tipped cannulas in specific regions for soft-tissue augmentation, s40 (August)

EDS-spondylocheirodysplastic: molecular basis for (RR), 1363

EEC syndrome: skeletal and radiographic findings (RR), 115

Ehlers-Danlos kyphoscoliosis (VI)

molecular basis for (RR), 1362

skeletal and radiographic findings (RR), 115

Ehlers-Danlos syndrome, classical (I and II): skeletal and radiographic findings (RR), 115

Electrical signaling, biomimetic: application to photo-aging, 30

Electronic brachytherapy: for treatment of NMSC, study (CTR), 671

Electroplaning of linear verrucous epidermal nevi, 474

Elephantiasis nostras verrucosa treated by acitretin (CR), 402

elos Plus: FDA clearance (PP), 1133

Emerve[®] fillers

cheek enhancement with: efficacy, patient satisfaction, and safety of, s9 (January)

full-face rejuvenation with (Editorial), s4 (January)

perioral rejuvenation with: efficacy, patient satisfaction, and safety of, s17 (January)

periorbital rejuvenation with: efficacy, patient satisfaction, and safety of, s27 (January)

physical properties of, s5 (January)

Enfuvirtide: cutaneous injection-site reactions, e35

Epidermal growth factor (EGF) receptor

inhibitors-associated dermatologic toxicities: tretinoin prevention study (CTR), 780

Epidermal growth factor (EGF) serum, barley-produced: for photodamage and aging in facial skin, efficacy study, 613

Epidermal nevi, linear verrucous: electroplaning of, 474

Epidermal nevus syndrome: skeletal and radiographic findings (RR), 115

Epiduo[®] Gel: FDA approves pump dispenser for (PP), 274

Epithelial cells: ingenol mebutate-induced cell death patterns in, 1181

Er:YSGG laser: fractional laser skin resurfacing with, biophysical evaluation of, 637

Erivedge™ (vismodegib): FDA approves

Erivedge (vismodegib) for advanced basal cell carcinoma (PP), 546

Erythema dyschromicum perstans: gene (mode of inheritance) and clinical manifestations (RR), 997

Erythema elevatum diutinum: association with monoclonal gammopathy (RR), 532

Erythema multiforme, recurrent: multifocal, fixed-drug eruption masquerading as (CR), 244

Erythema nodosum leprosum (ENL), thalidomide-treated: TH17 cytokines in, 626

Erythema of rosacea: comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment (CTR), 1136, 1524

Erythematous lesions of vulva (CR), 110

Erythrodysesthesia, palmoplantar, capecitabine-induced (CR), 769

Erythropoietic porphyria, congenital: skeletal and radiographic findings (RR), 114

Essential blepharospasm: botulinum toxin treatment of, effects of dietary zinc and phytase supplementation on, 507

Essential fatty acid supplementation: evidence for supplement use in atopic dermatitis (NVR), 1247

Essential oil of *Melaleuca alternifolia* (tea tree oil, TTO): combination TTO and iodine treatment of molluscum contagiosum in children, 349

Etanercept

comparative study of LY2439821 and etanercept plaque psoriasis treatment (CTR), 1251, 1382

long-term: for severe generalized psoriasis in HIV infection, case study (CR), 413

psoriasis re-treatment with, efficacy study, 950
as sole treatment for grade I acute graft-versus-host disease (CTR), 276

Ethical issues: blunt-tipped microcannulas for filler injection: an ethical duty? (Editorial), s42 (August)

Ethnic skin

aging of: implications for treatment with soft tissue fillers (CV), s30 (August)

cultural competence and unique concerns with, 460

laser hair removal in: patient satisfaction and complications study, 191

Excellagen[®]: FDA clearance (PP), 778

Excimer laser phototherapy

combination 308 nm excimer laser, clobetasol spray, and calcitriol ointment for treatment of psoriasis and long-term maintenance (CR), 994

psoriasis protocols literature review, 92

Extremities: necrobiotic xanthogranuloma of (RR), 122

Eye findings: associated diseases (RR), 399

Eye rejuvenation: two-filler combination injection technique for brighter eyes, 1094

Eyebrow hypotrichosis: bimatoprost treatment of (CR), 106

Eyelid defects: lower eyelid defect reconstruction with a V to Y island flap (SC), 988

Eyelid dermatitis: contact allergens relevant to (RR), 657

F

Fabior™ Foam, 0.1%: FDA approval (PP), 886

Fabry disease: skeletal and radiographic findings (RR), 115

Facial acne vulgaris: dapson 5% gel effects in female vs male patients, efficacy and tolerability study, 1417

Facial attractiveness: feelings of, improvement by cheek augmentation, 1077

Facial dermatoses, inflammatory: clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194

Facial folds: BELOTERO Balance[®] for (PP), 131

Facial hyperpigmentation: comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatments, 964

Facial melasma: Lumixyl Topical Brightening System treatment of (CR), 660

Facial photodamage: tretinoin emollient cream 0.02% treatment, efficacy and safety study, 1036

Facial reconstruction, post-burn, with bovine-derived collagen/elastin matrix (SC), 866

Facial redness. See **Rosacea**

Facial restoration: marker for filling techniques in HIV patients with facial wasting, 202

Facial rhytides: combination radiofrequency and low-frequency PEFM treatment of, safety and efficacy, 1306

Facial tightening with advanced 4-MHz monopolar radiofrequency device, 1288

Facial wasting: marker for filling techniques in HIV patients with, 202

Facial wrinkles
BELOTERO Balance[®] for (PP), 131

Botulinum Toxin Type A Topical Gel treatment of: efficacy and safety study with lateral canthal lines, 38

combination radiofrequency and low-frequency PEFM treatment of, safety and efficacy, 1306

Familial dysautonomia (Riley-Day syndrome): skeletal and radiographic findings (RR), 115

Fanconi anemia: skeletal and radiographic findings (RR), 115

Feelings of attractiveness: improvement by cheek augmentation, 1077

Fertility: finasteride and: case report and literature review (CR), 1511

Feverfew: antioxidants in acne vulgaris and aging: focus on green tea and feverfew, s11 (September)

Fibrocell Science, Inc.: LAVIV™ (azficel-T) trial data (PP), 778

Fibrofolliculoma: disease associations (RR), 1237

Fillers
advances in (Editorial), 20

basic science: adverse effects, 1069

basic science: background and mechanisms of action, 1059

blunt-tipped cannulas for, 70

- blunt-tipped microcannulas for the injection of soft tissue fillers: a consensus panel assessment and recommendations, s33 (August)
- comparative study of injections of filler with microcannulas and hypodermic needles, 1098
- faculty usage in single sessions, quick poll, s29 (August)
- hyaluronic acid: comparative study of injection techniques for tear trough deformity treatment, e80
- hyaluronic acid: retrospective review of Belotero Basic for facial treatments, 1032
- hyaluronic acid: Tower Technique and Vertical Supraperiosteal Depot Technique: novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)
- hyaluronic acid: two-filler combination injection technique for brighter eyes, 1094
- hyaluronic acid fillers on the horizon: roundtable discussion, s26 (August)
- injected volume: decision-making, quick poll, s29 (August)
- international perspective on—from an American perspective, 1089
- microdroplet silicone (1,000 centistokes) emulsified with cross-linked hyaluronic acid, results, 1336
- new and emerging concepts (letter to the editor), s25 (August)
- new and emerging concepts: roundtable discussion, s12 (August)
- the new face of fillers: a multi-specialty CME initiative (Part II of II) (CME), s5 (August)
- the new face of fillers: a multi-specialty CME initiative: Supplement Part II of II (Editorial), s8 (August)
- the new face of fillers: integrating evidence, experience and a little imagination at the next frontier (Editorial), 20
- racial and ethnic differences in skin aging: implications for treatment (CV), s30 (August)
- safety of dermal fillers, 1053
- and “three curves of youth” (CV), s9 (August)
- Finasteride**
and fertility: case report and literature review (CR), 1511
- label changes (PP), 887
- Fitzpatrick skin types**
combination clindamycin phosphate 1.2% and BPO 2.5% treatment of acne in, efficacy and tolerability study, 643
- doxycycline once-daily capsules for rosacea monotherapy in, effectiveness and safety study, 1219
- Fixed-drug eruptions**, multifocal, masquerading as recurrent erythema multiforme (CR), 244
- Fla. 855061 5**: comparative study of Fla. 855061 5 and tretinoin cream 0.025% for photo-damaged skin and acne vulgaris treatments, safety and efficacy study, 737
- Fluorescence technology**, advanced: Schamberg's disease treatment with (CR), 528
- 2-FluorodeoxyArbutin (fda)**: effects on tyrosinase and melanization, studies, e28
- FLUOROPLEX®**: Aqua Pharmaceuticals acquisition of (PP), 423
- Folic acid**: effects of oral isotretinoin on serum folic acid levels, e23
- Follicular neoplasms**: disease associations (RR), 1237
- Follicular spicules of the nose**: association with monoclonal gammopathy (RR), 530
- Food and Drug Administration (FDA)**
acceptance of sNDA for Plagiis (PP), 668
- approval and launch of clindamycin phosphate and BPO 1.2%/5% gel (PP), 1009
- approval of Alma Lasers' skin resurfacing module Pixel RF (PP), 1521
- approval of butaconazole nitrate 2% vaginal cream (PP), 886
- approval of CIP-ISOTRETINOIN (PP), 886
- approval of Erivedge (vismodegib) for advanced basal cell carcinoma (PP), 546
- approval of Excellagen® (PP), 778
- approval of Fabior™ Foam, 0.1% (PP), 886
- approval of first generic version of Dovonex Cream (PP), 1134
- approval of Horizant® for postherpetic neuralgia (PP), 1009
- approval of MelaFind (NVR), 420
- approval of MiraDry® for sweating (PP), 1249
- approval of Nuvail for brittle nails (PP), 1370
- approval of Picato® (ingenol mebutate) gel for actinic keratoses, 547
- approval of Plagiis as topical anesthetic peel (PP), 1521
- approval of pump dispenser for Differin Gel (PP), 668
- approval of pump dispenser for Epiduo® Gel, 274
- approval of Sciton's JOULE ClearSense™ for onychomycosis (PP), 274
- approval of Sklice® lotion (PP), 669
- approval of Stemedica application for Stemedyne-MS (PP), 1370
- approval of Taclonex® topical suspension, 0.005%/0.064% for body plaque psoriasis (PP), 1521
- approval of Watson's generic Lidoderm® (PP), 1249
- clearance for ADVANTAGE™ (PP), 778
- clearance for elos Plus (PP), 1133
- clearance for NeutroPhase (PP), 1249
- denial of approval of Plagiis (PP), 778
- finasteride label changes (PP), 887
- Nomir Medical 510(k) application to (PP), 1370
- Orphan Drug designation for trabedersen for malignant melanoma (PP), 1134
- Orphan Status approval for PermaDerm (PP), 1010
- priority review to new drug application for vismodegib (PP), 131
- requires follow-up on TNF blocker malignancy cases (PP), 423
- safety for extended-release and long-acting opioid medications (PP), 1009
- warning regarding mercury (PP), 778
- warning to Lancome about wrinkle cream claims (PP), 1379
- Foot dermatitis**: contact allergens relevant to (RR), 657
- Foot eczema**: retapamulin 1% ointment treatment of hand and foot eczema, investigator-initiated study (CTR), 889
- Foot ulcers, diabetic**: skin product approved for, in Canada (PP), 1249
- Forehead defects**, complex: novel reconstructive technique and review of available methods for, 759
- Forehead lines**, hyperdynamic: comparative study of BTA preparations for, in men, 216
- Francois syndrome** (dermochochrocorneal dystrophy): skeletal and radiographic findings (RR), 115
- Free cartilage batten grafting**, nonanatomic, with second intention healing: for distal nose defects, 46
- Fucosidosis**: skeletal and radiographic findings (RR), 115
- Full-thickness defects**: reconstruction with bovine-derived collagen/elastin matrix: challenging cases and post-burn facial reconstruction (SC), 866
- G**
- Galderma Laboratories, LP**: FDA acceptance of sNDA for Plagiis (PP), 668
- Gardner syndrome**
histologic characteristics (RR), 1503
- molecular basis for (RR), 1362
- skeletal and radiographic findings (RR), 115
- Gastrointestinal disease**: psoriasis and its comorbidities, s8 (May)
- Gaucher syndrome**: skeletal and radiographic findings (RR), 115
- Gender differences**
in combination clindamycin phosphate 1.2% and BPO 2.5% benefits, 1440
- in dapsone 5% gel effects on facial acne vulgaris, efficacy and tolerability study, 1417
- Genodermatoses**: skeletal and radiographic findings (RR), 114
- Georgia Health Sciences University (GHSU)**: program spotlight (RR), 240
- Gevokizumab**: efficacy and safety in acne vulgaris (CTR), 1136, 1523
- Gianotti-Crosti syndrome**: associated with hepatitis A and influenza vaccination (RR), 260
- Glabellar lines**: muscle mass consideration in BoNTA treatment, 1041
- Glomeruloid hemangioma**: association with monoclonal gammopathy (RR), 531
- Glycerin body moisturizers/cosmetic niacinamide**: comparative studies of stratum corneum integrity benefits, 22
- Glyconate**: surgeon preference in selection of absorbable suture material study, 196
- Goldenhar syndrome** (oculo-auriculo-vertebral dysplasia): skeletal and radiographic findings (RR), 115
- Goltz syndrome**
molecular basis for (RR), 1362
- skeletal and radiographic findings (RR), 115
- Gorlin syndrome**: skeletal and radiographic findings (RR), 115
- Graft-versus-host disease**, acute, grade I: etanercept as sole treatment for (CTR), 276
- Granuloma annulare**: multicentric reticulohistiocytosis presenting as (RR), 1509
- Green tea**: antioxidants in acne vulgaris and aging: focus on green tea and feverfew, s11 (September)
- Green tea catechins**: biologic properties, proposed mechanisms of action, and clinical implications, e55
- Griscelli syndrome**
associated with hemophagocytic lymphohistiocytosis (RR), 1126
- gene (mode of inheritance) and clinical manifestations (RR), 998
- molecular basis for (RR), 1362
- Gruber, Murray**: In Memoriam, 453
- Guest Editorials**
Letter from the Guest Editor, s4 (May)
- Message from the Guest Editor, 686, 803, 906, 1030
- study of skin of color, 448
- H**
- H syndrome**: molecular basis for (RR), 1362
- Haim Munk disorder**: molecular basis for (RR), 1362
- Hair removal**
axillary: comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser for, 185
- axillary: Nd:YAG nm laser hair reduction treatment for, study, 59
- home laser treatments for unwanted hair (NVR), 666
- Palomar Vectus™ Laser for: launch announcement (PP), 1249
- Halcinonide**: clinical merits review, Current Clinical Solutions (December)
- Hale, Elizabeth K.**: JDD: celebrating 10 years of publishing excellence interview (Editorial), 297
- Hand dermatitis**: contact allergens relevant to (RR), 657
- Hand eczema**: retapamulin 1% ointment treatment of hand and foot eczema, investigator-initiated study (CTR), 889

- Hand-foot skin reaction** associated with sorafenib and sunitinib: effects on health-related QOL study, e61
- Hand-Schuller-Christian disease:** skeletal and radiographic findings (RR), 116
- Hanke, C. William:** JDD: celebrating 10 years of publishing excellence interview (Editorial), 681
- Harlequin fetus:** molecular basis for (RR), 1363
- Hartnup defect:** molecular basis for (RR), 1363
- Health Canada:** approval of Dermagraft for diabetic foot ulcers (PP), 1249
- Hemangiomas**
glomeruloid
association with monoclonal gammopathy (RR), 531
infantile
beta antagonist treatment for, review, 826
propranolol as first-line therapy for, preliminary results, 808
multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812
- Hemifacial spasm:** botulinum toxin treatment of: effects of dietary zinc and phytase supplementation on, 507
- Hemochromatosis**
gene (mode of inheritance) and clinical manifestations (RR), 997
skeletal and radiographic findings (RR), 115
- Hemophagocytic lymphohistiocytosis:** Griscelli syndrome associated with (RR), 1126
- Henry Ford Hospital Department of Dermatology Residency Training Program:** program spotlight, 1232
- Hepatitis A vaccination:** Gianotti-Crosti syndrome associated with hepatitis A and influenza vaccination (RR), 260
- Hepatitis B:** in ustekinumab-treated psoriasis (CR), 1498
- Hepatitis C:** necrolytic acral erythema (RR), 1370
- Herbal medicine**
antioxidants in acne vulgaris and aging: focus on green tea and feverfew, s11 (September)
green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications, e55
herbal medicine in dermatology: does natural = safe? (NVR), 774
identifying natural ingredients and their use in skin care (CME), s4 (September)
natural ingredients in atopic dermatitis, s7 (September)
natural ingredients in skin of color: managing hyperpigmentation, s16 (September)
- Hermansky-Pudlak syndrome**
gene (mode of inheritance) and clinical manifestations (RR), 998
molecular basis for (RR), 1362
- Herpes:** AIC316 for, phase II trial clearance (PP), 1133
- Herpes skin lesions:** comparative study of Dynaclear™ and 5% Acyclovir cream for, 209
- Hidradenitis suppurativa**
adalimumab for, efficacy and safety trial, s15 (May)
adalimumab for, Phase 3 trials (PP), 669
- Hidrotic ectodermal dysplasia:** skeletal and radiographic findings (RR), 115
- Hispanics**
combination clindamycin phosphate 1.2% and BPO 2.5% gel treatment of acne vulgaris in, post-hoc analysis, 455
skin cancer prevention trends among US Hispanics, systematic review, 580
- HIV infection**
facial marker for aesthetic facial restoration in patients with facial wasting, 202
long-term etanercept for severe generalized psoriasis in, case study (CR), 413
- HL-009 liposomal gel:** safety and efficacy in adult patients with atopic dermatitis (CTR), 1012
- Home laser treatments** for acne, aging, and unwanted hair (NVR), 666
- Homocystinuria:** skeletal and radiographic findings (RR), 116
- Horizant®:** FDA approval for postherpetic neuralgia (PP), 1009
- Howard University Hospital Department of Dermatology and Residency Program** history (RR), 991
- Hoyeraal Heirsson syndrome:** molecular basis for (RR), 1361
- Hsiung, Sherry:** JDD: celebrating 10 years of publishing excellence interview (Editorial), 1268
- HUMIRA®** (adalimumab): Phase 3 trials for hidradenitis suppurativa (PP), 669
- Huriez syndrome:** skeletal and radiographic findings (RR), 116
- Hyaluronic acid, cross-linked:** liquid silicone (SilikonR) emulsified with, 1336
- Hyaluronic acid fillers**
with 0.3% lidocaine hydrochloride, injectable: for superficial, vertical perioral lines and superficial, horizontal, lateral canthal lines (CTR), 134
comparative study of injection techniques for tear trough deformity treatment, e80
Emerve® fillers: physical properties of, s5 (January)
on the horizon: roundtable discussion, s26 (August)
retrospective review of Belotero Basic for facial treatments, 1032
Tower Technique and Vertical Supraperiosteal Depot Technique: novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)
two-filler combination injection technique for brighter eyes, 1094
- Hydrogel vehicles:** transepidermal water loss (TEWL) and corneometry with, in atopic dermatitis treatment, 181
- Hydrophilic Index (HI):** comparative study of moisturizers via pH and hydrophilic fraction measurements, 633
- Hyperhidrosis, focal axillary:** Nd:YAG nm laser hair reduction treatment study, 59
- Hypericum perforatum:** comparative study of Dynamiclear™ and 5% Acyclovir cream for, 209
- Hyperimmunoglobulin E syndrome:** skeletal and radiographic findings (RR), 116
- Hyperpigmentation**
comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatments, 964
comparative study of SMA-432 and 4% hydroquinone skin brightening for, efficacy and safety of, 1478
laser treatment of melasma (CTR), 134
natural ingredients in skin of color: managing hyperpigmentation, s16 (September)
- Hyperpigmentation kits:** comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatment, 964
- Hyperplasia**
pseudoeplitheliomatous: pseudoeplitheliomatous hyperplasia and transepidermal elimination in lepromatous leprosy (CR), 1232
sebaceous: novel 1,720-nm laser treatment, report, 1323
- Hypertension, white coat:** in Mohs micrographic surgery, e18
- Hypodermic needles:** comparative study of injections of filler with microcannulas and hypodermic needles, 1098
- Hypomelanosis of Ito**
gene (mode of inheritance) and clinical manifestations (RR), 998
skeletal and radiographic findings (RR), 116
- Hypopigmented cutaneous sarcoidosis:** responsive to minocycline (CR), 385
- Hypopigmented mycosis fungoides:** gene (mode of inheritance) and clinical manifestations (RR), 998
- Hypotrichosis, eyebrow:** bimatoprost treatment of (CR), 106
- Ichthyosis, lamellar:** skeletal and radiographic findings (RR), 116
- Imaging, optical:** for margin delineation of non-melanoma skin cancers study (CTR), 672
- Imiquimod 5% cream:** actinic keratoses treatment with, observational study, 574
- Immunotherapy**
BMS-936558: interim results, Phase 1 trial (PP), 886
ingenol mebutate: potential for further development of cancer immunotherapy, 1156
- Impetigo**
NovaBay announces successful End-of-Phase 2a FDA meeting for NVC-422 program for (PP), 1010
oral antibiotics most commonly prescribed for, 489
- In Memoriam:** Murray Gruber MD, 453
- IncobotulinumtoxinA** (Bocouture®/Xeomin®) to cheek: efficacy and safety in rosacea (CTR), 1523
comparative study of incobotulinumtoxinA and onabotulinumtoxinA, meta-analysis, 731
- Incontinentia pigmenti:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Infantile hemangiomas**
beta antagonist treatment for, review, 826
proliferating: topical timolol 0.5% for, prospective study (CTR), 424
propranolol as first-line therapy for, preliminary results, 808
- Infected atopic dermatitis:** retapamulin 1% ointment treatment, pilot study, 858
infectious disease. See also specific diseases nanotechnology and diagnosis of, 846
- Inflammation**
cutaneous: improved co-culture model results, 834
UVB effects on, co-culture model of, 834
- Inflammatory acne:** NicAzel dietary supplement management of, 1428
- Inflammatory bowel disease:** acne treatment, s10 (June)
- Inflammatory facial dermatoses:** clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
- Infliximab** (Remicade): and increased incidence of basal cell carcinoma (CR), 655
- Influenza vaccination:** Gianotti-Crosti syndrome associated with hepatitis A and influenza vaccination (RR), 260
- Ingenol mebutate** (Picato®) gel
-induced cell death patterns in normal and cancer epithelial cells, 1181
FDA approves Picato® (ingenol mebutate) gel for actinic keratoses, 547
potential for further development of cancer immunotherapy, 1156
- Inherited skin disorders.** See also *specific disorders*
molecular basis for selected inherited skin disorders (RR), 1361
- Injection sites**
cutaneous reactions to enfuvirtide, e35
lupus-like reaction to subcutaneous interferon-α at (CR), 393
repetitive same-site insulin injections: acanthosis nigricans from, e85

Injection techniques

comparative study of HA injection techniques for tear trough deformity treatment, e80

Tower Technique and Vertical Supraperiosteal Depot Technique: novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)

Innocutis Holdings, LLC: agreement with DARA for Bionect® (PP), 668

Insulin injections, repetitive same-site: acanthosis nigricans from, e85

Insulin resistance: psoriasis and its comorbidities, s9 (May)

Intense pulsed light: melasma treatment and use, review, 1316

Interferon- α , subcutaneous: lupus-like reaction at injection sites (CR), 393

Interleukin 12/23 inhibitors: nail psoriasis treatment with TNF- α or IL12/23 inhibitors, review of studies, 939

Interleukin 12-engineered TILs

metastatic melanoma treatment with, phase II study (CTR), 1382

metastatic melanoma treatment with, safety and efficacy study (CTR), 1251

International Society for Dermatologic Surgery (ISDS): training in dermatologic surgery (Editorial), 800

Intravenous immunoglobulin (IVIG): treatment of ulcerated necrobiosis lipoidica with IVIG and methylprednisolone (CR), 256

Iodine: combination TTO and iodine treatment of molluscum contagiosum in children, 349

Ipilimumab: for treatment of metastatic melanoma (NVR), 271

Ireland: Allergan plans Botox manufacturing expansion in (PP), 423

Iso-Kikuchi syndrome: skeletal and radiographic findings (RR), 116

Isoconazole nitrate: combination isoconazole nitrate and diflucortolone valerate tinea inguinalis treatment, retrospective study, e70

Isotretinoin

oral: effects on serum folic acid levels, e23

skeletal and radiographic findings with use of (RR), 114

Itto: hypomelanosis of

gene (mode of inheritance) and clinical manifestations (RR), 998

skeletal and radiographic findings (RR), 116

Ixekizumab (LY2439821): comparative study of LY2439821 and etanercept plaque psoriasis treatment (CTR), 1251, 1382

J

JAK inhibitors: in psoriasis, a promising new treatment modality, 913

Japanese skin: Er:YSGG fractional laser skin resurfacing, biophysical evaluation of, 637

JOULE ClearSense™: Sciton's FDA clears JOULE ClearSense™ for onychomycosis (PP), 274

Journal of Drugs in Dermatology (JDD): celebrating 10 years of publishing excellence (Editorial), 17, 155, 297, 445, 569, 681, 799, 898, 1028, 1150, 1268, 1398

K

Kasabach-Merritt syndrome: histologic characteristics (RR), 1504

Keratodermas, palmoplantar, inherited (RR), 767

Kindler syndrome: skeletal and radiographic findings (RR), 116

Klippel-Trenaunay syndrome: skeletal and radiographic findings (RR), 116

L**Lamelar ichthyosis**

molecular basis for (RR), 1363

skeletal and radiographic findings (RR), 116

Lancome: FDA warning about wrinkle cream claims (PP), 1379

Laser technology

alexandrite laser, long-pulse: benign pigmented lesion treatment with, 1327

carbon dioxide (CO₂) laser: combination radio-frequency and CO₂ laser treatment of periorbital syringoma (CR), 879

carbon dioxide (CO₂) laser: comparative study of ultrapulse-mode and superpulse-mode fractionated CO₂ laser photoaged skin treatment, 1310

carbon dioxide (CO₂) laser: novel superficial and deep fractional system in treatment of patients with skin of color, safety and efficacy of, 1331

carbon dioxide (CO₂) laser: pathergic response to fractional CO₂ (CR), 1122

comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment of periorbital wrinkles, pilot trial (CTR), 781, 1013

comparative study of pulsed dye laser and 1064-nm Nd:YAG laser treatment of facial redness, pilot study (CTR), 888

comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser, for axillary hair removal, 185

Er:YSGG laser: fractional skin resurfacing with, in Japanese skin, 637

excimer laser phototherapy: combination 308 nm excimer laser, clobetasol spray, and calcitriol ointment treatment of psoriasis and long-term maintenance (CR), 994

excimer laser phototherapy: psoriasis protocols literature review, 92

fractional laser skin resurfacing, 1274

hair removal in ethnic skin, patient satisfaction and complications study, 191

home treatments for acne, aging, and unwanted hair (NVR), 666

melasma treatment (CTR), 134

Nd:YAG laser, 1320 nm: onychomycosis appearance improvement study (CTR), 548

Nd:YAG laser, fractional: nonablative Q-switched 1,064-nm Nd:YAG laser to rejuvenate photoaged skin: a pilot case series, 1300

Nd:YAG laser, sub-millisecond: toenail onychomycosis treatment, 496

Nd:YAG laser hair reduction: focal axillary hyperhidrosis treatment study, 59

novel 1,720-nm laser: sebaceous hyperplasia treatment, report, 1323

Palomar Vectus™ Laser: launch announcement (PP), 1249

quality-switched, evolution of, 1296

V-Raser diode laser system: onychomycosis treatment study (CTR), 1137

Laugier-Hunziker syndrome: gene (mode of inheritance) and clinical manifestations (RR), 997

LAVIV™ (azficel-T): trial data (PP), 778

Lebwohl, Mark: JDD: celebrating 10 years of publishing excellence interview (Editorial), 1150

Leg ulcers: spray-on cell-based therapy (PP), 1133

Lentiginos: multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812

LEO Pharma Inc.

FDA approval for Taclonex® topical suspension, 0.005%/0.064% for body plaque psoriasis (PP), 1521

LEO® Quality Care Program for plaque psoriasis patients (PP), 274

LEO® Quality Care Program for plaque psoriasis patients (PP), 274

LEOPARD syndrome

gene (mode of inheritance) and clinical manifestations (RR), 997

molecular basis for (RR), 1361

skeletal and radiographic findings (RR), 116

Lepromatous leprosy

giant PPD reaction with positive Quantiferon-TB Gold in (letter to the editor), 1151

pseudoepitheliomatous hyperplasia and transepidermal elimination in (CR), 1232

Leprosy

gene (mode of inheritance) and clinical manifestations (RR), 998

lepromatous: giant PPD reaction with positive Quantiferon-TB Gold in (letter to the editor), 1151

lepromatous: pseudoepitheliomatous hyperplasia and transepidermal elimination in (CR), 1232

M. lepromatosis: emerging strain or species? (Editorial), 158

M. lepromatosis: identification, in Singapore, 168

skeletal and radiographic findings (RR), 114

thalidomide-treated: TH17 cytokines in, 626

Leprosy-like illness: with *M. lepromatosis*, in patient from Ontario, Canada (CR), 229

Letters to the editor

crowdsourcing in eczema research: a novel method of data collection, 1153

doxycycline safety studies, 20

giant PPD reaction with positive Quantiferon-TB Gold in a patient with lepromatous leprosy, 1151

metformin-induced pseudoporphyria, 1272

microRNA 150 in humans and murine contact sensitivity, 1152

new and emerging concepts in soft tissue fillers, s25 (August)

new inhibitors of polo-like kinase 1 function and their emerging role in attenuating tumor growth in systemic malignancies, 1402

Leukemia cutis (LC) (RR), 416

Leukocytoclastic vasculitis (LCCV): association with monoclonal gammopathy (RR), 532

Levis, William: JDD: celebrating 10 years of publishing excellence interview (Editorial), 569

Lichen striatus: combination therapy in children, case series and review (CR), 872

Lidocaine

diluted, for subcutaneous infiltration and virtually painless local anesthesia, e39

topical patch 5%: FDA approval of (PP), 1249

Lidoderm®

FDA approval of Watson's generic Lidoderm® (PP), 1249

patent challenge settlement (PP), 887

LiftActiv Serum 10: introduction by Vichy Laboratories (PP), 1133

Linear prokeratosis, generalized (RR), 772

Linear verrucous epidermal nevi (LVEN): electroplanning of, 474

Lip augmentation: six steps to the "perfect" lip, 1081

Lipodystrophy, partial: molecular basis for (RR), 1363

Lipoid proteinosis: skeletal and radiographic findings (RR), 116

Liquid silicone (Silikon®): emulsified with cross-linked hyaluronic acid, results, 1336

Livedo reticularis associated with rasagiline (Azilect) (CR), 764

Local anesthesia

FDA approval of Pliaglis as topical anesthetic peel (PP), 1521

virtually painless: diluted lidocaine for subcutaneous infiltration, e39

L'Oreal: comparative study of Fla. 855061 5 and tretinoin cream 0.025% for photodamaged skin and acne vulgaris treatments, safety and efficacy study, 737

Lower eyelid defects: reconstruction with a V to Y island flap (SC), 988

Lower eyelid-upper cheek augmentation: two-filler combination injection technique for brighter eyes, 1094

Luliconazole Solution 10%: safety and efficacy in distal subungual onychomycosis of the toenails (CTR), 1013

Lumixyl Topical Brightening System: treatment of mild to moderate facial melasma with (CR), 660

Lupus-like reaction to subcutaneous interferon- α at injection sites (CR), 393

Lutronic, Inc.: FDA clearance for ADVANTAGE™ (PP), 778

LY2439821 (ixekizumab): comparative study of LY2439821 and etanercept plaque psoriasis treatment (CTR), 1251, 1382

Lymphoepithelioma-like carcinoma with mycosis fungoides (RR), 663

Lymphohistiocytosis, hemophagocytic: Griscelli syndrome associated with (RR), 1126

Lymphoma
cutaneous T-cell: SHP 141 effects on, safety and tolerability study (CTR), 1252, 1383
psoriasis and its comorbidities, s9 (May)

M

Mafucci syndrome: skeletal and radiographic findings (RR), 116

Malignancy
chronic ulcers: when to consider malignancy? (NVR), 1006
emerging role of PLK1 inhibitors in attenuating tumor growth in systemic malignancies (letter to the editor), 1402
FDA requires follow-up on TNF blocker cases (PP), 423

Malignant melanoma: Orphan Drug designation for trabedersen for (PP), 1134

Mandibuloacral lipodystrophy: molecular basis for (RR), 1363

Marfan syndrome: skeletal and radiographic findings (RR), 116

Mayo Clinic Dermatology Residency Training Program: program spotlight (RR), 104

Mayoral, Flor A.: JDD: celebrating 10 years of publishing excellence interview (Editorial), 898

McCune-Albright syndrome
gene (mode of inheritance) and clinical manifestations (RR), 997
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 116

MelaFind: FDA approval of (NVR), 420

Melaleuca alternifolia: essential oil of (tea tree oil, TTO): combination TTO and iodine treatment of molluscum contagiosum in children, 349

Melanization: effects of deoxyArbutin and its derivatives on, studies, e28

Melanoma
-detecting technologies and standard of care (Editorial), 1270
adrenergic urticaria and rheumatoid arthritis with (CR), 409
BI 2536 antitumor activities against, in vitro, 587
metastatic: IL-12 modified tumor white blood cells treatment of, phase I/II study (CTR), 1382
metastatic: IL-12 modified tumor white blood cells treatment of, safety and efficacy study (CTR), 1251
metastatic: novel therapies for treatment of (NVR), 271
metastatic: PV-10 for, Phase 3 trial, 423
metastatic uveal: comparative study of sunitinib and dacarbazine treatment of (CTR), 548
new diagnostic test detects signaling enzyme (PP), 131

pedunculated, case report (RR), 269
transection on initial biopsy: effects on outcome (NVR), 1518

Melasma
intense pulsed light treatment and use, review, 1316
laser treatment of (CTR), 134
Lumixyl Topical Brightening System treatment of (CR), 660

Menkes disease
molecular basis for (RR), 1363
skeletal and radiographic findings (RR), 116

Mercury: FDA warning regarding (PP), 778

Merz Aesthetics: BELOTERO Balance® for facial wrinkles and folds, 131

Metabolic syndrome: psoriasis and its comorbidities, s7 (May)

Metastatic melanoma
comparative study of sunitinib and dacarbazine treatment of (CTR), 548
IL-12 modified tumor white blood cells treatment of, phase I/II study (CTR), 1382
IL-12 modified tumor white blood cells treatment of, safety and efficacy study (CTR), 1251
novel therapies for treatment of (NVR), 271
PV-10 treatment of, Phase 3 trial, 423

Metformin-induced pseudoporphyria (letter to the editor), 1272

Methyl aminolevulinate photodynamic therapy: urticaria after, in nevoid basal cell carcinoma syndrome (CR), 1364

Methylprednisolone
combination IVIG and methylprednisolone treatment of ulcerated necrobiosis lipoidica (CR), 256
combination methylprednisolone aceponate 0.1% and nickel sulfate-induced eczema (PP), 1379

Microcystic adnexal carcinoma: disease associations (RR), 1238

Microdermabrasion: molecular mechanisms unraveled, e5, e10

Micrographic surgery, Mohs: white coat hypertension in, e18

microRNA 150 in humans and murine contact sensitivity (letter to the editor), 1152

Minocycline: hypopigmented cutaneous sarcoidosis responsive to (CR), 385

MiraDry®: FDA approval for sweating (PP), 1249

MIST Therapy after cosmetic surgery procedures, effectiveness study (CTR), 135

Mohs micrographic surgery: white coat hypertension in, e18

Moisturizers
adjunctive use of SPF 30 with tretinoin 0.05%, split-face study, 1104
comparative study of pH and hydrophilic fractions, 633

Molluscum contagiosum (MC): combination TTO and iodine treatment of, in children, 349

Monoclonal gammopathy: skin disorders associated with (RR), 530

Moy, Ronald L.: JDD: celebrating 10 years of publishing excellence interview (Editorial), 1398

Muir-Torre syndrome
histologic characteristics (RR), 1503
molecular basis for (RR), 1361

Multiple endocrine neoplasia (MEN)
type I: histologic characteristics (RR), 1503
type IIa: histologic characteristics (RR), 1503
type IIa: molecular basis for (RR), 1362
type IIb: histologic characteristics (RR), 1503
type IIb: molecular basis for (RR), 1362
type IIb: skeletal and radiographic findings (RR), 116

Multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812

Multispectral digital microscope (MDM): optical imaging of skin cancers for margin delineation of non-melanoma skin cancers study (CTR), 672

Muscle mass considerations in BoNTA glabellar line treatment, 1041

Mycobacterium lepromatosis
emerging strain or species? (Editorial), 158
identification of, in Singapore, 168
leprosy-like illness with, in patient from Ontario, Canada (CR), 229

Mycobacterium tuberculosis: chronic psoriasis improvement after TNF- inhibitor therapy for (CR), 119

Mycosis fungoides: lymphoepithelioma-like carcinoma with (RR), 663

Myxed neurothekeoma of nose (CR), 252

N

Naftifine 1% gel: seborrheic dermatitis of scalp treatment, efficacy and safety study, 514

Nail changes: drug-induced pyogenic granulomas, review (CR), 262

Nail-patella syndrome: skeletal and radiographic findings (RR), 116

Nail psoriasis: treatment with TNF- or IL12/23 inhibitors, review of studies, 939

NAME/LAMB syndromes: gene (mode of inheritance) and clinical manifestations (RR), 997

Nanotechnology
and diagnosis of dermatological infectious disease, 846
nanoemulsions: novel topical antiviral NB-001 cold sore treatment, safety and efficacy study, 970

Nasal Ala reconstruction: with crus helix composite graft: stepladder approach (SC), 376

National Capital Consortium Dermatology Residency Training Program: program spotlight (RR), 390

National Psoriasis Foundation: consensus guidelines (PP), 546

National Rosacea Society Awards: grants for medical research (PP), 130

Natural ingredients
evidence for supplement use in atopic dermatitis (NVR), 1245
green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications, e55
herbal medicine in dermatology: does natural = safe? (NVR), 774
identifying natural ingredients and their use in skin care (CME), s4 (September)
natural ingredients in atopic dermatitis, s7 (September)
natural ingredients in skin of color: managing hyperpigmentation, s16 (September)

NB-001: novel topical antiviral NB-001 cold sore treatment, safety and efficacy study, 970

Nd:YAG laser
comparative study of pulsed dye laser and 1064-nm Nd:YAG laser treatment of facial redness, pilot study (CTR), 888
comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser, for axillary hair removal, 185
fractional, nonablative Q-switched 1,064-nm Nd:YAG laser to rejuvenate photoaged skin: a pilot case series, 1300
hair reduction, focal axillary hyperhidrosis treatment study, 59
hair removal in ethnic skin, patient satisfaction and complications study, 191
1320 nm, onychomycosis appearance improvement study (CTR), 548
Q-switched (RevLite), melasma treatment study (CTR), 134
sub-millisecond 1,064 nm, toenail onychomycosis treatment, 496

Neck wrinkles: Pellevé™ treatment of, prospective study (CTR), 135

- Necrobiotic xanthogranuloma**
association with monoclonal gammopathy (RR), 531
of extremities (RR), 122
- Necrolytic acral erythema:** recent case description and discussion (RR), 1370
- Neoplasms:** disease associations (RR), 1237
- NeoStrata® Skin Active:** antiaging effects, study results, 1447
- Neurofibromatosis I**
gene (mode of inheritance) and clinical manifestations (RR), 997
histologic characteristics (RR), 1504
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 116
- Neurofibromatosis II**
gene (mode of inheritance) and clinical manifestations (RR), 997
molecular basis for (RR), 1362
- Neurothekeoma, myxed:** of nose (CR), 252
- NeuroPhase:** FDA clearance for (PP), 1249
- Nevus sebaceous:** disease associations (RR), 1237
- News, Views & Reviews (NVR)**
childhood atopic dermatitis risk factors: truth or fiction, 126
chronic ulcers: when to consider malignancy?, 1006
does transecting a melanoma on initial biopsy affect the outcome?, 1518
evidence for supplement use in atopic dermatitis, 1245
herbal medicine in dermatology: does natural = safe?, 774
home laser treatments: acne, aging, and unwanted hair, 666
MelaFind is approved by the FDA: where does it fit in dermatology?, 420
novel therapies for the treatment of metastatic melanoma, 271
the outer aspect of our inner anxiety: the skinny on stress, 883
psychology and psychiatry in the dermatologist's office: an approach to delusions of parasitosis, 543
radiation dermatitis: current perspectives and future directions, 1127
RNA interference in dermatology: current perspectives and future directions, 1373
- NicAzol:** inflammatory acne management with, 1428
- Nickel sulfate-induced eczema:** methylprednisolone aceponate 0.1% and (PP), 1379
- Nitric oxide-releasing nanoparticles (NO-np):** nitrosoglutathione generating: strategy for combating *P aeruginosa*-infected wounds, 1471
- Nitroglycerin (RECTIV™ Ointment):** Aptalis Pharma announces agreement to market RECTIV™ in the U.S. (PP), 547
- S-nitrosoglutathione (GSNO):** as antimicrobial agent against *P aeruginosa*, 1471
- Nodules:** extramedullary plasmacytoma presenting as asymptomatic nodules on buttocks and thighs (RR), 1244
- Nomir Medical Technologies:** 510(k) application to Food and Drug Administration (FDA) (PP), 1370
- Noonan syndrome**
molecular basis for (RR), 1361
skeletal and radiographic findings (RR), 116
- Nose defects**
alar: reconstruction with crus helix composite graft: stepladder approach (SC), 376
distal nose: nonanatomic free cartilage batten grafting with second intention healing for, 46
distal nose: reconstruction with hatchet and bilobed flaps, 99
lower half of the nose: reconstruction of (SC), 226
myxed neurothekeoma (CR), 252
- Nose reconstruction**
back to basics: reconstruction of defects on the lower half of the nose (SC), 226
with hatchet and bilobed flaps, 99
- NovaBay Pharmaceuticals**
FDA clearance for NeutroPhase (PP), 1249
successful End-of-Phase 2a FDA meeting for NVC-422 program (PP), 1010
- Novartis:** new AIN457 (secukinumab) phase 2 data (PP), 1379
- Nuvail:** FDA approval for brittle nails (PP), 1370
- Nuvo Research:** FDA approval of Pliaglis as topical anesthetic peel (PP), 1521
- NVC-422 program:** NovaBay announces successful End-of-Phase 2a FDA meeting for (PP), 1010
- O**
- Oatmeal:** colloidal oatmeal formulations as adjunct treatments in atopic dermatitis, 804
- Obagi (OMP):** comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatments, 964
- Occipital horn syndrome:** molecular basis for (RR), 1363
- Oculo-auriculo-vertebral dysplasia (Goldenhar syndrome):** skeletal and radiographic findings (RR), 115
- Oculocutaneous albinism (OCA)**
gene (mode of inheritance) and clinical manifestations (RR), 998
molecular basis for (RR), 1362, 1363
- Older adults:** trends in psoriasis outpatient health care practices in the United States, 950
- OnabotulinumtoxinA (Botox®/Vistabel®)**
Allergan plans manufacturing expansion in Ireland (PP), 423
comparative study of incobotulinumtoxinA and onabotulinumtoxinA, meta-analysis, 731
rosacea treatment regimen, e76
- Onchocerciasis:** gene (mode of inheritance) and clinical manifestations (RR), 998
- Onychomycosis**
Nd:YAG laser 1320 nm improvement of appearance of (CTR), 548
Sciton's FDA clears JOULE ClearSense™ for (PP), 274
tavaborole treatment of, Phase 3 trials (PP), 275
toenail, distal subungual: Luliconazole Solution 10% safety and efficacy in (CTR), 1013
toenail: sub-millisecond Nd:YAG 1,064 nm laser treatment of, 496
V-Raser diode laser system treatment study (CTR), 1137
- Opioids:** FDA safety for extended-release and long-acting opioid medications (PP), 1009
- Optical imaging** for margin delineation of non-melanoma skin cancers study (CTR), 672
- Optimal Balance Technology™:** Emervel® fillers: physical properties of, s5 (January)
- Oral antibiotics** most commonly prescribed for impetigo, 489
- Oral-facial-digital syndrome:** skeletal and radiographic findings (RR), 116
- Oregon Health & Science University Department of Dermatology:** program spotlight (RR), 653
- Osteogenesis imperfecta:** skeletal and radiographic findings (RR), 116
- Over-the-counter topical skincare products:** literature review, 220
- Oxidative stress:** role in acne vulgaris, 742
- P**
- Pachydermoperiostosis:** skeletal and radiographic findings (RR), 116
- Pachyonychia congenita type 2:** histologic characteristics (RR), 1504
- Paclitaxel-treated breast cancer:** paclitaxel-associated subungual pyogenic granuloma in (CR), 262
- Palmoplantar erythrodysesthesia:** capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia (CR), 769
- Palmoplantar keratoderma, inherited (RR), 767**
- Palomar Vectus™ Laser:** launch announcement (PP), 1249
- Papillary renal cell carcinoma, type 2:** histologic characteristics (RR), 1503
- Papillon-Lefevre syndrome**
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 116
- Papulopustular rosacea**
doxycycline modified-release capsules for, effectiveness and safety study, 703
rationale for combination therapy for, 838
- Parasitosis:** delusions of
approach to (NVR), 543
successful treatment of patients previously labeled as having (CR), 1506
- Pathology:** dermatopathology bodies review (RR), 876
- Patient adherence to treatment**
novel approach to increasing acne treatment regimens, s14 (June)
tips for enhancing, s15 (June)
- PD-0360324:** in active cutaneous lupus erythematosus, safety, tolerability, and efficacy study of (CTR), 424, 1136
- Pedunculated melanoma:** case report (RR), 269
- Pellevé™ treatment gel:** prospective study (CTR), 135
- Pellevé™ wrinkle treatment handpiece:** prospective study (CTR), 135
- Pemphigus**
sirolimus treatment of (CTR), 277
treatment re-evaluation, 1200
- Percutaneous absorption:** regional variations in, overview, e48
- Perez, Maritza I.:** JDD: celebrating 10 years of publishing excellence interview (Editorial), 1028
- Perforating dermatosis:** with primary sclerosing cholangitis, case review (RR), 881
- Perioral rejuvenation**
with Emervel® fillers: efficacy, patient satisfaction, and safety of, s17 (January)
injectable hyaluronic acid with 0.3% lidocaine hydrochloride for (CTR), 134
- Periorbital rejuvenation**
comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment for, pilot trial (CTR), 781, 1013
with Emervel® fillers: efficacy, patient satisfaction, and safety of, s27 (January)
- Periorbital syringoma:** combination radiofrequency and CO2 laser treatment (CR), 879
- PermaDerm:** FDA Orphan Status approval for (PP), 1010
- Perrigo Company:** FDA approval of butaconazole nitrate 2% vaginal cream (PP), 886
- Peutz-Jeghers syndrome**
gene (mode of inheritance) and clinical manifestations (RR), 997
molecular basis for (RR), 1362
- Phosphodiesterase-4 (PDE-4) inhibitors:** Anacor Pharmaceuticals announces positive preliminary results (PP), 275
- Photo-aging**
BIOEFFECT EGF serum efficacy study, 613
biomimetic electrical signaling application to, 30
comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatments, 964
comparative study of ultrapulse-mode and superpulse-mode fractionated CO2 laser photoaged skin treatment, 1310
fractional, nonablative Q-switched 1,064-nm Nd:YAG laser to rejuvenate photoaged skin: a pilot case series, 1300
L-ascorbic acid serum treatment study, 51

Photodamage

- BIOEFFECT EGF serum efficacy study, 613
 comparative study of Fla. 855061 5 and tretinoin cream 0.025% treatments, safety and efficacy study, 737
 tretinoin 0.02% cream reduction of, efficacy and safety pilot study, 83
 tretinoin 0.02% cream reduction of, efficacy and safety study, 1036

Photodynamic therapy (PDT)

- combination ALA-PDT chemopreventative effects on multiple actinic keratoses with skin cancer history, 593
 combination blue light ALA-PDT treatment of actinic keratoses on upper extremities, phase 2 study, 1483
 methyl aminolevulinate: urticaria after, in nevroid basal cell carcinoma syndrome (CR), 1364

Phototherapy

- combination alefacept and nbUVB phototherapy for psoriasis, efficacy study, 929
 effects of topical pimecrolimus 1% on long-term suberythral UVB-irradiated epidermal Langerhans cells, in mice, e25
 UVB effects on inflammatory processes, coculture model, 834

Photothermolysis: comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment of periorbital wrinkles, pilot trial (CTR), 781, 1013

Phytase supplementation: effects on botulinum toxin treatments, 507

Picato® (ingenol mebutate) gel: FDA approves Picato® (ingenol mebutate) gel for actinic keratoses, 547

Piebaldism: gene (mode of inheritance) and clinical manifestations (RR), 998

Pigmentation disorders

- genes (modes of inheritance) and clinical manifestations (RR), 997
 multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812

Pigmented lesions, benign: long-pulse alexandrite laser treatment of, 1327

Pilomatricoma: disease associations (RR), 1237

Pimecrolimus: effects on long-term suberythral UVB-irradiated epidermal Langerhans cells, in mice, e25

Pinta: gene (mode of inheritance) and clinical manifestations (RR), 998

Pipeline Previews (PP)

- AiCuris herpes drug clears Phase II Trial, 1133
 Allergan plans Botox manufacturing expansion in Ireland, 423
 Alpharma launches clotrimazole and beta-methasone dipropionate topical cream (PP), 423
 Anacor Pharmaceuticals and tavorole for onychomycosis, 275
 Anacor Pharmaceuticals announces positive preliminary results, 275
 anti-PD-1 immunotherapy (BMS-936558) and Phase 1 trial, 886
 Aptalis Pharma announces agreement to market RECTIV™ in the U.S., 547
 Aqua Pharmaceuticals acquires FLUORO-PLEX®, 423
 Atralin® gel promotes tretinoin penetration, 130
 BELOTERO Balance® for facial wrinkles and folds, 131
 DARA and Bionect®, 668
 Dermablend professional, 1009
 FDA and Pliaglis, 668
 FDA approval and launch of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel, 1009
 FDA approval for Horizant® for postherpetic neuralgia (PP), 1009
 FDA approval of CIP-ISOTRETINOIN, 886

FDA approves Alma Lasers' skin resurfacing module, 1521

FDA approves Erivedge (vismodegib) for advanced basal cell carcinoma, 546

FDA approves first generic version of Dovonex Cream, 1134

FDA approves Nuvail for brittle nails, 1370

FDA approves Picato® (ingenol mebutate) gel for actinic keratoses, 547

FDA approves pump dispenser for Epiduo® Gel, 274

FDA approves pump dispenser of Differin Gel, 668

FDA approves Sorilux™ Foam, 0.005% for plaque psoriasis of the scalp, 1379

FDA approves Stemedica application, 1370
 FDA cleared Excellagen®, 778

FDA denies approval for Pliaglis, 778

FDA grants PermaDerm Orphan Status, 1010

FDA grants priority review to new drug application for vismodegib, 131

FDA Orphan Drug designation for trabectedin for malignant melanoma, 1134

FDA requires follow-up on TNF blocker malignancy cases, 423

FDA safety for extended-release and long-acting opioid medications, 1009

FDA warning regarding mercury, 778

FDA warns Lancome about wrinkle cream claims, 1379

finasteride label changes, 887

generic equivalents of Clobex® shampoo and Clobex® topical lotion, 423

HUMIRA® (adalimumab) for hidradenitis suppurativa, 669

LAVIV™ (azficel-T) trial data, 778

LEO Pharma Inc receives FDA approval for Taclonex® topical suspension, 0.005%/0.064% for body plaque psoriasis, 1521

LEO® Quality Care Program for plaque psoriasis patients, 274

LUTRONIC® announces FDA clearance for ADVANTAGE™, 778

methylprednisolone aceponate 0.1% and nickel sulfate-induced eczema, 1379

MiraDry® is FDA approved for sweating, 1249

National Psoriasis Foundation releases consensus guidelines, 546

National Rosacea Society Awards new grants for medical research, 130

new melanoma diagnostic test detects signaling enzyme, 131

Nomir Medical 510(k) application to FDA, 1370

NovaBay announces successful End-of-Phase 2a FDA meeting, 1010

NovaBay receives FDA clearance for NeutroPhase, 1249

Novartis and AIN457 (secukinumab), 1379

Palomar Vectus™ Laser for laser hair removal, 1249

Perrigo receives FDA approval, 886

Phase 3 trial of PV-10 for metastatic melanoma, 423

Pliaglis receives FDA approval as topical anesthetic peel, 1521

PreCision Dermatology acquires assets of Triax Pharmaceuticals, 778

Sanofi, Coca-Cola join efforts on beauty drinks, 1521

Sanofi announces FDA approval of Sklice® lotion, 669

Sciton's FDA clears JOULE ClearSense™ for onychomycosis, 274

skin product approved for diabetic foot ulcers in Canada, 1249

spray-on cell-based therapy and leg ulcers, 1133

Star Scientific's Rock Creek Pharmaceuticals, Inc, launches Anatabloc® face cream, 1521

Stiefel receives FDA approval of Fabior™ Foam, 0.1% (PP), 886

Syneron receives FDA clearance for elos Plus, 1133

Trius Therapeutics and tedizolid, 275

Ulthera to expand operations, 546

Vichy Laboratories introduces LiftActiv Serum 10, 1133

Watson announces Lidoderm® patent challenge settlement, 887

Watson's generic Lidoderm® receives FDA approval, 1249

Pixel QS Nd:YAG laser device: fractional, nonablative Q-switched 1,064-nm Nd:YAG laser to rejuvenate photoaged skin: a pilot case series, 1300

Pixel RF: FDA approval (PP), 1521

Plane xanthoma, diffuse normolipemic: association with monoclonal gammopathy (RR), 531

Plaque psoriasis

- body: FDA approval of Taclonex® topical suspension, 0.005%/0.064% for (PP), 1521
 clobetasol propionate 0.05% spray effects on health-related QOL, 1348
 clobetasol propionate 0.05% spray effects on signs and symptoms, 1455
 CNTO 1959 treatment, safety and efficacy of (CTR), 425
 CNTO 1959 treatment study (CTR), 548
 comparative study of LY2439821 and etanercept treatment (CTR), 1251, 1382
 CP-690,550 treatment, efficacy and safety study (CTR), 276

FDA approval of Sorilux™ Foam, 0.005% for (PP), 1379

LEO® Quality Care Program for plaque psoriasis patients (PP), 274

secukinumab 300 mg s.c. treatment, long-term effects study (CTR), 1251

secukinumab 300 mg s.c. treatment, phase II study (CTR), 1382

secukinumab treatment, safety and efficacy of (CTR), 424

ustekinumab treatment in a patient with Down syndrome (CR), 998

ustekinumab treatment review, 160

Plasmacytoma

association with monoclonal gammopathy (RR), 530

extramedullary, presenting as asymptomatic nodules on buttocks and thighs (RR), 1244

Pliaglis

acceptance of sNDA for (PP), 668

FDA approval as topical anesthetic peel (PP), 1521

FDA denies approval for (PP), 778

POEMS syndrome: histologic characteristics (RR), 1503

Poliglecaprone 25: surgeon preference in selection of absorbable suture material study, 196

Poliosis, acitretin-induced, with concurrent alopecia (CR), 247

Polo-like kinase 1 (PLK1): new inhibitors of polo-like kinase 1 function and their emerging role in attenuating tumor growth in systemic malignancies (letter to the editor), 1402

Poly-L-lactic acid (PLLA): Sculptra®: a practical primer to volumization with poly-L-lactic acid, 1046

Polychondritis, relapsing: skeletal and radiographic findings (RR), 114

Porokeratosis, linear, generalized (RR), 772

Postauricular region: as training ground for local flaps (SC), 1358

Postherpetic neuralgia: FDA approval of Horizant® for (PP), 1009

Pre-pubertal patients. See also Children acne treatment, s10 (June)

PreCision Dermatology: acquisition of Triax Pharmaceuticals assets (PP), 778

Pregnancy: severe psoriasis treatment with ustekinumab during (CR), 1240

- Primary sclerosing cholangitis:** perforating dermatosis with, case review (RR), 881
- Progeria**
molecular basis for (RR), 1363
skeletal and radiographic findings (RR), 116
- Propionibacterium acnes**
combination clindamycin phosphate 1.2% and tretinoin 0.025% antimicrobial effects on, 1434
short-contact BP 9.8% emollient foam treatment on the back, comparative study, 830
- Propranolol:** as first-line therapy for infantile hemangiomas, preliminary results, 808
- Proteus syndrome**
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 116
- Proton pump inhibitors:** cutaneous reactions to, case-control study, e43
- Provectus Pharmaceuticals:** Phase 3 trial of PV-10 for metastatic melanoma, 423
- Pseudoepitheliomatous hyperplasia** and transepidermal elimination in lepromatous leprosy (CR), 1232
- Pseudomonas aeruginosa infection:** nitrosogluathione generating nitric oxide-releasing nanoparticle (NO-np) strategy for combating, 1471
- Pseudoporphyria,** metformin-induced (letter to the editor), 1272
- Pseudoxanthoma elasticum**
histologic characteristics (RR), 1504
molecular basis for (RR), 1363
- Psoriasis**
in African-Americans, caregivers' survey, 478
biologic therapy for: considerations for when to initiate, s11 (May)
body: FDA approval of Taclonex® topical suspension, 0.005%/0.064% for (PP), 1521
clobetasol propionate 0.05% spray effects on health-related QOL, 1348
clobetasol propionate 0.05% spray effects on signs and symptoms, 1455
clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
CNTO 1959 treatment study (CTR), 548
combination 308 nm excimer laser, clobetasol spray, and calcitriol ointment treatment and long-term maintenance (CR), 994
combination alefacept and nbUVB phototherapy treatment, efficacy study, 929
comparative study of LY2439821 and etanercept treatment (CTR), 1251, 1382
CP-690,550 treatment, efficacy and safety study (CTR), 276
etanercept re-treatment, efficacy study, 950
excimer laser phototherapy protocols literature review, 92
facial: clocortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
FDA approval of Sorilux™ Foam, 0.005% for (PP), 1379
FDA approval of Taclonex® topical suspension, 0.005%/0.064% for (PP), 1521
in HIV infection: long-term etanercept for, case study (CR), 413
JAK inhibitors in: a promising new treatment modality, 913
LEO® Quality Care Program for plaque psoriasis patients (PP), 274
nail: treatment with TNF- α or IL12/23 inhibitors, review of studies, 939
older adult outpatient health care practices in the United States, 950
PSOLAR study: design, utility, and preliminary results, 1210
psoriasis and its comorbidities, s5 (May)
of scalp: FDA approval of Sorilux™ Foam, 0.005% for (PP), 1379
secukinumab 300 mg s.c. treatment, long-term effects study (CTR), 1251
secukinumab 300 mg s.c. treatment, phase II study (CTR), 1382
secukinumab treatment, safety and efficacy study (CTR), 424
TNF- α inhibitor therapy for M. tuberculosis infection improvement of (CR), 119
ustekinumab effects on health-related quality of life in Korean and Taiwanese patients, PEARL study results, 943
ustekinumab safety in, 907
ustekinumab-treated: hepatitis B in (CR), 1498
ustekinumab treatment during pregnancy (CR), 1240
ustekinumab treatment in a patient with Down syndrome (CR), 998
ustekinumab treatment review, 160
- Psoriasis Clinical Development Program:** long-term safety experience of ustekinumab update, 300
- Psoriasis verrucosa:** adalimumab treatment of (CR), e74
- Psoriatic arthritis**
psoriasis and its comorbidities, s6 (May)
ustekinumab treatment review, 160
- Psychological disease**
approach to delusions of parasitosis (NVR), 543
psoriasis and its comorbidities, s8 (May)
- Pulsed dye laser (PDL):** comparative study of pulsed dye laser and 1064-nm Nd:YAG laser treatment of facial redness, pilot study (CTR), 888
- Pulsed electromagnetic fields (PEMF):** combination radiofrequency and low-frequency PEMF treatment of facial rhytides, safety and efficacy, 1306
- Pustular dermatosis,** subcorneal: association with monocolonal gammopathy (RR), 532
- PV-10:** Phase 3 trial for metastatic melanoma, 423
- Pyoderma gangrenosum:** association with monocolonal gammopathy (RR), 531
- Pyogenic granulomas,** drug-induced, adjacent to and beneath the nail (CR), 262
- ## Q
- Quality of life**
comparative study of combination BPO 5% and clindamycin 1% and adapalene 0.1% for acne vulgaris treatment, 714
effects of clobetasol propionate 0.05% spray on, in patients with plaque psoriasis, 1348
effects of hand-foot skin reaction associated with sorafenib and sunitinib on, study, e61
effects of ustekinumab on, in Korean and Taiwanese psoriasis patients, PEARL study results, 943
psoriasis and its comorbidities, s8 (May)
- Quality-switched lasers**
evolution of, 1296
fractional, nonablative Q-switched 1,064-nm Nd:YAG laser to rejuvenate photoaged skin: a pilot case series, 1300
RevLite: melasma treatment study (CTR), 134
- Quantiferon-TB Gold assay:** giant PPD reaction with positive Quantiferon-TB Gold in a patient with lepromatous leprosy (letter to the editor), 1151
- ## R
- Racial differences.** See also **Ethnic skin; Skin of color**
in skin aging: implications for treatment with soft tissue fillers (CV), s30 (August)
- Radiation dermatitis:** current perspectives and future directions (NVR), 1127
- Radiofrequency technology**
combination radiofrequency and CO2 laser treatment of periorbital syringoma (CR), 879
combination radiofrequency and low-frequency PEMF treatment of facial rhytides, safety and efficacy, 1306
facial tightening with an advanced 4-MHz monopolar radiofrequency device, 1288
FDA approval of Pixel RF (PP), 1521
- Radiography:** findings associated with dermatological disorders (RR), 104
- Rasagiline (Azilect):** livedo reticularis associated with (CR), 764
- Rash, EGFR-associated:** tretinoin prevention study (CTR), 780
- Reactive oxygen species (ROS):** caffeine protection against acute ROS-induced necrosis, 1342
- RECTIV™ (nitroglycerin) Ointment:** Aptalis Pharma announces agreement to market RECTIV™ in the U.S. (PP), 547
- Redness, facial.** See **Rosacea**
- Reed syndrome:** histologic characteristics (RR), 1503
- Reflectance confocal microscopy:** in vivo features of discoid lupus erythematosus (CR), 1111
- Reflex sympathetic dystrophy:** skeletal and radiographic findings (RR), 114
- Refsum syndrome**
molecular basis for (RR), 1362
skeletal and radiographic findings (RR), 116
- Regenicin:** FDA Orphan Status approval for PermaDerm (PP), 1010
- Rejuvenation**
comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment for, pilot trial (CTR), 781, 1013
with Emervel® fillers: efficacy, patient satisfaction, and safety of, s17 (January)
fillers and the "three curves of youth" (CV), s9 (August)
injectable hyaluronic acid with 0.3% lidocaine hydrochloride for (CTR), 134
two-filler combination injection technique for brighter eyes, 1094
- Remicade (infliximab):** and increased incidence of basal cell carcinoma (CR), 655
- Renal cell carcinoma**
bullous pemphigoid associated with renal cell carcinoma and invasive squamous cell carcinoma (CR), 234
papillary type 2: histologic characteristics (RR), 1503
- Research grants:** National Rosacea Society Awards grants (PP), 130
- Resident Rounds (RR)**
adverse cutaneous reactions to chemotherapy agents, 1120
amyloidoses of dermatologic significance, 250
contact allergens relevant to dermatitis in special locations, 657
dermatologic syndromes and their histologic characteristics, 1503
dermatopathology bodies review, 876
Duke Dermatology residency training program program spotlight, 1115
extramedullary plasmacytomas presenting as asymptomatic nodules on the buttocks and thighs, 1240
eye findings, 399
follicular, apocrine, sebaceous, and eccrine neoplasms and their disease associations, 1237
generalized linear porokeratosis, 772
Georgia Health Sciences University program spotlight, 240
Gianotti-Crosti syndrome associated with hepatitis A and influenza vaccination, 260
Griscelli syndrome associated with hemophagocytic lymphohistiocytosis, 1126
Henry Ford Hospital Department of Dermatology Residency Training Program program spotlight, 1232
Howard University Hospital Department of Dermatology and Residency Program history, 991
inherited palmoplantar keratoderms, 767
leukemia cutis, 416
lymphoepithelioma-like carcinoma with mycosis fungoides, 663

- Mayo Clinic Dermatology Residency Training Program program spotlight, 104
- molecular basis for selected inherited skin disorders, 1361
- multicentric reticulohistiocytosis presenting as granuloma annulare, 1509
- National Capital Consortium Dermatology Residency Training Program program spotlight, 390
- necrobiotic xanthogranuloma of the extremities, 122
- necrolytic acral erythema, 1370
- Oregon Health & Science University Department of Dermatology program spotlight, 653
- pedunculated melanoma, 269
- performing dermatosis with primary sclerosing cholangitis, 881
- pigmentation disorders, 997
- San Antonio Uniformed Services Health Education Consortium program spotlight, 870
- skeletal and radiographic findings associated with dermatological disorders, 114
- skin disorders associated with monoclonal gammopathy, 530
- St. Joseph Mercy Health System Dermatology Residency Program program spotlight, 1497
- tumor stage acne keloidalis nuchae treated with surgical excision and secondary intention healing, 540
- University of Iowa Hospitals and Clinics (UIHC) program spotlight, 762
- USF Department of Dermatology and Cutaneous Surgery Residency Training Program program spotlight, 524
- Virginia Commonwealth University Health System Department of Dermatology program spotlight, 1356
- Vogt-Koyanagi-Harada Disease in an African-American Female (CR), 1004
- Retapamulin**
- 1% ointment for infected atopic dermatitis, pilot study, 858
 - 1% ointment treatment of hand and foot eczema, investigator-initiated study (CTR), 889
- Reticulate pigmentation of Kitamura:** gene (mode of inheritance) and clinical manifestations (RR), 997
- Reticulohistiocytosis, multicentric**
- presenting as granuloma annulare (RR), 1509
 - skeletal and radiographic findings (RR), 114
- Retinoids**
- combination therapy for acne vulgaris, optimizing, 313
 - combination therapy for lichen striatus treatment in children, case series and review (CR), 872
- RevLite (Q-switched Nd:YAG laser):** melasma treatment study (CTR), 134
- Rheumatoid arthritis:** adrenergic urticaria and rheumatoid arthritis with melanoma (CR), 409
- Rhytids (rhytides).** *See also Facial wrinkles; Neck wrinkles*
- botulinum toxin treatment of: effects of dietary zinc and phytase supplementation on, 507
 - combination radiofrequency and low-frequency PEMF treatment of, safety and efficacy, 1306
 - treatment of: with devices (CTR), 135
 - treatment of: with injectables (CTR), 134
- Riley-Day syndrome (familial dysautonomia):** skeletal and radiographic findings (RR), 115
- Rituximab:** autoimmune mucocutaneous blistering skin disease treatment with, literature review, 622
- RNA interference:** current perspectives and future directions (NVR), 1373
- Robins, Perry:** *JDD:* celebrating 10 years of publishing excellence interview (Editorial), 17
- Rock Creek Pharmaceuticals, Inc.:** launching of Anatabloc® face cream (PP), 1521
- Rosacea**
- acne & rosacea: thinking outside the box (Editorial), 1400
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% treatment: summary of a placebo-controlled, double-blind trial, 1410
 - combination topical aminocaproic acid and Vanicream rosacea treatment, single-site study, 888
 - comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment (CTR), 1136, 1524
 - comparative study of pulsed dye laser and 1064-nm Nd:YAG laser treatment, pilot study (CTR), 888
 - doxycycline once-daily capsule treatment in patients with skin of color, effectiveness and safety study, 1219
 - incobotulinumtoxinA to cheek efficacy and safety in (CTR), 1523
 - as inflammatory disorder, 694
 - onabotulinumtoxinA treatment regimen, e76
 - papulopustular: doxycycline modified-release capsules for, effectiveness and safety study, 703
 - papulopustular: rationale for combination therapy for, 838
 - state of the art diagnosis and treatment of, 725
- Rosacea-prone skin:** primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response, 694
- Rothmund-Thomson syndrome**
- molecular basis for (RR), 1361
 - skeletal and radiographic findings (RR), 117
- Rubinstein-Taybi syndrome**
- molecular basis for (RR), 1362
 - skeletal and radiographic findings (RR), 117
- Russell-Silver syndrome:** skeletal and radiographic findings (RR), 117
- S**
- Sadick, Neil:** *JDD:* celebrating 10 years of publishing excellence interview (Editorial), 799
- Safety issues**
- with dermal fillers, 1053
 - with herbal medicine in dermatology (NVR), 774
 - with ustekinumab in psoriasis, 907
- Safety studies**
- adalimumab for hidradenitis suppurativa, efficacy and safety trial, s15 (May)
 - adalimumab for hidradenitis suppurativa, Phase 3 trials (PP), 669
 - Altanax ointment for secondarily infected atopic dermatitis (CTR), 276
 - anakinra/kineret for atopic dermatitis, pilot study (CTR), 671
 - apremilast treatment of allergic contact or atopic dermatitis, 341
 - L-ascorbic acid serum on photo-aged skin, 51
 - Botulinum Toxin Type A Topical Gel treatment of moderate-to-severe lateral canthal lines, 38
 - clobetasol propionate 0.05% spray plaque psoriasis treatment, 1455
 - clo cortolone pivalate 0.1% cream for inflammatory facial dermatoses, 1194
 - combination adapalene-BPO and doxycycline followed by longer-term adapalene-BPO acne vulgaris treatment, 174
 - combination calcipotriol 0.005% and betamethasone dipropionate 0.05% vitiligo treatment, e52
 - combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening acne vulgaris treatment, 748
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% acne rosacea treatment, 333
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% acne vulgaris treatment, 318
 - combination radiofrequency and low-frequency PEMF treatment of facial rhytides, 1306
 - comparative study of CD07805/47 gel 0.5% and azelaic acid gel 15% erythema of rosacea treatment (CTR), 1136, 1524
 - comparative study of Fla. 855061 5 and tretinoin cream 0.025% for photodamaged skin and acne vulgaris treatments, 737
 - comparative study of LY2439821 and etanercept plaque psoriasis treatment (CTR), 1251, 1382
 - comparative study of single alexandrite laser vs combined alexandrite and Nd:YAG laser for axillary hair removal, 185
 - comparative study of SMA-432 and 4% hydroquinone skin brightening, 1478
 - CP-690,550 plaque psoriasis treatment, Phase 3 study (CTR), 889
 - diclofenac sodium 3% gel actinic keratosis management, 600
 - doxycycline (letter to the editor), 20
 - doxycycline modified-release capsules for papulopustular rosacea, effectiveness and safety study, 703
 - doxycycline once-daily capsules for rosacea in patients with skin of color, 1219
 - Emerve!® fillers for cheek enhancement, s9 (January)
 - Emerve!® fillers for perioral rejuvenation, s17 (January)
 - Emerve!® fillers for periorbital rejuvenation, s27 (January)
 - gevokizumab for acne vulgaris (CTR), 1136, 1523
 - HL-009 liposomal gel in adult patients with mild to moderate atopic dermatitis (CTR), 1012
 - IL-12 modified tumor white blood cells treatment of metastatic melanoma (CTR), 1251
 - incobotulinumtoxinA to cheek for rosacea (CTR), 1523
 - Luliconazole Solution 10% in distal subungual onychomycosis of the toenails (CTR), 1013
 - naftifine 1% gel treatment of seborrheic dermatitis of scalp, pilot study, 514
 - novel topical antiviral NB-001 cold sore treatment, 970
 - PD-0360324 treatment of active cutaneous lupus erythematosus (CTR), 424, 1136
 - RA-18C3 in moderate to severe acne vulgaris, phase II study (CTR), 780
 - retrospective review of hyaluronic acid Belotero Basic for facial treatments, 1032
 - secukinumab treatment of chronic plaque-type psoriasis (CTR), 424
 - SHP 141 effects on cutaneous T-cell lymphoma (CTR), 1252, 1383
 - tretinoin cream 0.02% for reduction of dermato-heliosis, pilot study, 83
 - tretinoin emollient cream 0.02% for facial photodamage, 1036
 - ustekinumab long-term safety experience, 300
- Salicylic acid:** combination salicylic acid and sandalwood oil acne treatment, open-label study, 1403
- San Antonio Uniformed Services Health Education Consortium:** program spotlight (RR), 870
- Sandalwood oil:** combination salicylic acid and sandalwood oil acne treatment, open-label study, 1403
- Sanofi**
- FDA approval of Sklice® lotion (PP), 669
 - Sanofi, Coca-Cola join efforts on beauty drinks (PP), 1521
- SAPHO syndrome:** skeletal and radiographic findings (RR), 117
- Sarcoidosis**
- as adverse effect of TNF inhibitors, retrospective case review, 609

- hypopigmented, responsive to minocycline (CR), 385
- Sarnoff, Deborah S.:** JDD: celebrating 10 years of publishing excellence interview (Editorial), 445
- Scabies:** comparative study of 8% and 10% topical sulfur ointment treatments, 357
- Scalp**
- contact allergens relevant to dermatitis of (RR), 657
 - plaque psoriasis of: FDA approval of Sorilux™ Foam, 0.005% for (PP), 1379
 - seborrheic dermatitis of: naftifine 1% gel treatment of, pilot study, 514
- Scar:** immunohistochemical and ultrastructural effects of Contractubex® gel on formation of, study, 74
- Schamberg's disease:** advanced fluorescence technology treatment of (CR), 528
- Schimmelpenning syndrome:** histologic characteristics (RR), 1504
- Schnitzler syndrome**
- association with monoclonal gammopathy (RR), 531
 - skeletal and radiographic findings (RR), 117
- Schopf Shulz Passarge syndrome:** molecular basis for (RR), 1362
- Sciton:** Sciton's FDA clears JOULE ClearSense™ for onychomycosis (PP), 274
- Scleredema:** association with monoclonal gammopathy (RR), 531
- Scleromyxedema:** association with monoclonal gammopathy (RR), 531
- Scoliosis:** Ehlers-Danlos kyphoscoliosis (VI): skeletal and radiographic findings (RR), 115
- Sculptra®:** volumization with poly-L-lactic acid, 1046
- Sebaceous hyperplasia:** novel 1,720-nm laser treatment, report, 1323
- Sebaceous neoplasms:** disease associations (RR), 1237
- Seborrheic dermatitis**
- facial: clo cortolone pivalate 0.1% cream treatment of, efficacy and safety study, 1194
 - of scalp: naftifine 1% gel treatment of, pilot study, 514
- Secondarily infected atopic dermatitis:** Altabax ointment treatment of, safety and efficacy study (CTR), 276
- Secondary intention healing:** tumor stage acne keloidalis nuchae treated with surgical excision and (RR), 540
- Secukinumab (AIN457)**
- chronic plaque psoriasis treatment, long-term effects study (CTR), 1251
 - chronic plaque psoriasis treatment, phase II study (CTR), 1382
 - chronic plaque psoriasis treatment, safety and efficacy of (CTR), 424
 - new Novartis phase 2 data (PP), 1379
- Shire Regenerative Medicine:** skin product approved for diabetic foot ulcers in Canada (PP), 1249
- SHP 141:** effects on cutaneous T-cell lymphoma, safety and tolerability study (CTR), 1252, 1383
- Silicone,** microdroplet (1,000 centistokes), emulsified with cross-linked hyaluronic acid, results, 1336
- Silikon® (liquid silicone):** emulsified with cross-linked hyaluronic acid, results, 1336
- Simvastatin and ezetimibe (Vytorin):** alopecia areata treatment, pilot study (CTR), 780
- Sipple syndrome:** histologic characteristics (RR), 1503
- Sirolimus:** pemphigus treatment evaluation (CTR), 277
- Sitosterolemia:** molecular basis for (RR), 1363
- Sjogren-Larsson syndrome:** molecular basis for (RR), 1362
- Skeleton:** skeletal findings associated with dermatological disorders (RR), 104
- Skin brightening:** comparative study of SMA-432 and 4% hydroquinone for, efficacy and safety of, 1478
- Skin cancer.** See also **Melanoma;** specific types chemopreventative effects of ALA PDT on multiple actinic keratoses with history of, 593
- chronic ulcers: when to consider malignancy? (NVR), 1006
- optical imaging for margin delineation of non-melanoma skin cancers study (CTR), 672
- prevention and latest treatments (Editorial), 572
- prevention trends among US Hispanics, systematic review, 580
- Skin grafts,** full-thickness: correct sizing of (SC), 520
- Skin of color**
- basal cell carcinoma in, 484
 - combination clindamycin phosphate 1.2% and BPO 2.5% gel treatment of acne in adolescents, 818
 - natural ingredients in: managing hyperpigmentation, s16 (September)
 - novel superficial and deep CO₂ fractional system in treatment of patients with, safety and efficacy of, 1331
 - rosacea in: doxycycline once-daily monotherapy for, effectiveness and safety study, 1219
 - study of (Guest Editorial), 448
 - tinea capitis treatment options in, 852
 - top dermatologic conditions in, nationally representative data, 466
- Skin Perfector Pigment Correcting Primer:** Dermablend introduction of (PP), 1009
- SkinMedica (SKM):** comparative study of SkinMedica and Obagi facial hyperpigmentation and photo-aging treatments, 964
- Sklice® lotion:** FDA approval of (PP), 669
- Soft tissue fillers**
- blunt-tipped cannulas for, 70
 - blunt-tipped cannulas for: a consensus panel assessment and recommendations, s33 (August)
 - blunt-tipped cannulas for: in specific regions (Editorial), s40 (August)
 - new and emerging concepts (letter to the editor), s25 (August)
 - new and emerging concepts: roundtable discussion, s12 (August)
 - racial and ethnic differences in skin aging: implications for treatment (CV), s30 (August)
- Solaraze® (diclofenac sodium 3% gel):** for actinic keratosis management, efficacy and safety study, 600
- Sorafenib:** hand-foot skin reaction associated with, effects on health-related QOL study, e61
- Sorilux™ Foam, 0.005%:** FDA approval for plaque psoriasis of the scalp (PP), 1379
- Spasm, hemifacial:** botulinum toxin treatment of: effects of dietary zinc and phytase supplementation on, 507
- Special Topics**
- basal cell carcinoma in skin of color, 484
 - basic science of dermal fillers: adverse effects, 1069
 - basic science of dermal fillers: background and mechanisms of action, 1059
 - brighter eyes: combined upper cheek and tear trough augmentation: a systematic approach utilizing two complementary hyaluronic acid fillers, 1094
 - cheek augmentation improves feelings of facial attractiveness, 1077
 - chemopreventative effects of ALA PDT with multiple actinic keratoses and skin cancer history, 593
 - clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial, 1410
 - colloidal oatmeal formulations as adjunct treatments in atopic dermatitis, 804
 - combination clindamycin phosphate 1.2% and

- BPO 2.5% gel treatment of acne in adolescents with skin of color, 818
- combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening acne vulgaris treatment, efficacy and safety study, 748
- combination salicylic acid and sandalwood oil acne treatment, open-label study, 1403
- combination therapy for lichen striatus in children, case series and review (CR), 872
- comparison of skin irritancy following application of combination clindamycin/tretinoin and benzoyl peroxide/adapalene, 1422
- comparison of ultrapulse-mode and superpulse-mode fractionated carbon dioxide lasers on photoaged skin, 1310
- diclofenac sodium 3% gel for actinic keratosis management, efficacy and safety study, 600
- efficacy and tolerability of dapson 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable, 1417
- the evolution of quality-switched lasers, 1296
- facial tightening with an advanced 4-MHz monopolar radiofrequency device, 1288
- filler injections with blunt-tip microcannula, 1098
- fractional, nonablative Q-switched 1,064-nm neodymium YAG laser to rejuvenate photoaged skin: a pilot case series, 1300
- fractional laser skin resurfacing, 1274
- gender differences in combination clindamycin phosphate 1.2% and BPO 2.5% benefits, 1440
- inflammatory acne management with a novel prescription dietary supplement, 1428
- ingenol mebutate: potential for further development of cancer immunotherapy, 1156
- ingenol mebutate-induced cell death patterns in normal and cancer epithelial cells, 1181
- international perspective on fillers in dermatology—from an American perspective, 1089
- JAK inhibitors in psoriasis: a promising new treatment modality, 913
- multiples: markers for special considerations in diagnosis, therapy, and prognosis, 812
- muscle mass consideration in glabellar line treatment with botulinum toxin type A, 1041
- propranolol as first-line therapy for infantile hemangiomas: preliminary results, 808
- pseudoepitheliomatous hyperplasia and trans-epidermal elimination in lepromatous leprosy: does T-cell plasticity play a role? (CR), 1232
- psoriasis in African-Americans, caregivers' survey, 478
- retrospective review of hyaluronic acid Belotero Basic for facial treatments, 1032
- review of beta antagonist treatment for infantile hemangioma, 826
- safety and efficacy of a new device combining radiofrequency and low-frequency PEMF for the treatment of facial rhytides, 1306
- safety and efficacy of a novel superficial and deep carbon dioxide fractional system in the treatment of patients with skin of color, 1331
- safety of dermal fillers, 1053
- safety of ustekinumab in psoriasis, 907
- sarcoidosis as adverse effect of TNF inhibitors, retrospective case review, 609
- Sculptra®: a practical primer to volumization with poly-L-lactic acid, 1046
- six steps to the "perfect" lip, 1081
- the study of simple chemicals in animals and man: mechanisms of contact sensitivity, 1166
- T helper cell subsets in the development of atopic dermatitis, 1174
- treatment of benign pigmented lesions using a long-pulse alexandrite laser, 1327

treatment of melasma and the use of intense pulsed light: a review, 1316

treatment of nail psoriasis with TNF- or IL12/23 inhibitors, 939

treatment of psoriasis and long-term maintenance with 308 nm excimer laser, clobetasol spray, and calcitriol ointment (CR), 994

treatment of sebaceous hyperplasia with a novel 1,720-nm laser, 1323

trends in older adult psoriasis outpatient health care practices in the United States, 950

ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome (CR), 998

ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL Trial, 943

in vivo antibacterial effects of tretinoin-clindamycin and clindamycin alone on propionibacterium acnes, 1434

Spencer, James M.: *JDD*: celebrating 10 years of publishing excellence interview (Editorial), 155

Squamous cell carcinoma
electronic brachytherapy for NMSC study (CTR), 671

invasive: bullous pemphigoid associated with renal cell carcinoma and invasive squamous cell carcinoma (CR), 234

Squaric acid dibutyl ester (SADBE): combination TCA 50% and cantharidin 0.7% for response to, 1228

St. Joseph Mercy Health System Dermatology Residency Program: program spotlight, 1497

Staphylococcus aureus, nasal: clearance with triple antibiotic ointment, 1490

Steinert disease: histologic characteristics (RR), 1504

Stelara® (ustekinumab): plaque psoriasis and psoriatic arthritis treatment review, 160

Stemedyne-MSc: FDA approval of Stemedica application for (PP), 1370

Steroids. See also Corticosteroids
combination therapy for lichen striatus treatment in children, case series and review (CR), 872

Stiefel: FDA approval of Fabior™ Foam, 0.1% (PP), 886

Stratum corneum
comparative studies of stratum corneum integrity benefits of cosmetic niacinamide/glycerin body moisturizers vs conventional body moisturizers, 22

Stremedica Cell Technologies, Inc.: FDA approval of IND application for Stemedyne-MSc (PP), 1370

Stress
the outer aspect of our inner anxiety: the skinny on stress (NVR), 883

oxidative: role in acne vulgaris, 742

Sturge-Weber syndrome: skeletal and radiographic findings (RR), 117

Subcorneal pustular dermatosis: association with monoclonal gammopathy (RR), 532

Sulfur: comparative study of 8% and 10% topical sulfur ointment for scabies treatment, 357

Sunitinib
comparative study of sunitinib and dacarbazine treatment of metastatic uveal melanoma (CTR), 548

hand-foot skin reaction associated with effects on health-related QOL study, e61

Supplements
essential fatty acid: evidence for supplement use in atopic dermatitis (NVR), 1247

evidence for supplement use in atopic dermatitis (NVR), 1245

novel NicAzal: inflammatory acne manage-

ment with, 1428

phytase: effects on botulinum toxin treatments, 507

vitamin D: atopic dermatitis treatment, clinical trial study, 327

vitamin D: evidence for supplement use in atopic dermatitis (NVR), 1245

zinc: effects on botulinum toxin treatments, 507

zinc: evidence for supplement use in atopic dermatitis (NVR), 1246

Surgeons: preference in selection of absorbable suture material study, 196

Surgery
delay techniques for local flaps (SC), 1108

excision and secondary intention healing for tumor stage acne keloidalis nuchae (RR), 540

lower eyelid defect reconstruction with a V to Y island flap (SC), 988

Mohs micrographic: white coat hypertension in, e18

nasal Ala reconstruction with crus helix composite graft: stepladder approach (SC), 376

new simple, safe, and easy solution for upper lip dermabrasion (SC), 649

postauricular training ground for local flaps (SC), 1358

reconstruction of defects on the lower half of the nose (SC), 226

reconstruction of full-thickness defects with bovine-derived collagen/elastin matrix: challenging cases and post-burn facial reconstruction (SC), 866

reconstructive technique and review of available methods for complex forehead defects (SC), 759

sizing of full-thickness skin grafts (SC), 520

Surgical Corner (SC)
back to basics: reconstruction of defects on the lower half of the nose, 226

complex forehead defects: a novel reconstructive technique and review of available methods, 759

correct sizing of full-thickness skin grafts, 520

delay techniques for local flaps, 1108

nasal Ala reconstruction with crus helix composite graft: stepladder approach, 376

a new simple, safe, and easy solution for upper lip dermabrasion, 649

reconstruction of a lower eyelid defect with a V to Y island flap, 988

reconstruction of full-thickness defects with bovine-derived collagen/elastin matrix: challenging cases and post-burn facial reconstruction, 866

“wet behind the ears”: postauricular training ground for local flaps, 1358

Suture material, absorbable: surgeon preference in selection study, 196

Sweat production
FDA approval of MiraDry® for (PP), 1249

Nd:YAG nm laser hair reduction effects study, in focal axillary hyperhidrosis, 59

Sweet syndrome
association with monoclonal gammopathy (RR), 531

skeletal and radiographic findings (RR), 114

Syneron Medical Ltd.: FDA clearance for elos Plus (PP), 1133

Syphilis, congenital: skeletal and radiographic findings (RR), 114

Syringocystadenoma papilliferum (SCAP): disease associations (RR), 1238

Syringoma
combination radiofrequency and CO₂ laser treatment (CR), 879

disease associations (RR), 1238

Systemic lupus erythematosus: capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia (CR), 769

T

T-cell lymphoma: SHP 141 effects on, safety and tolerability study (CTR), 1252, 1383

T cells
adoptive transfer for treatment of metastatic melanoma (NVR), 272

helper cell subsets in atopic dermatitis development, 1174

plasticity, role in pseudoepitheliomatous hyperplasia and transepidermal elimination in lepromatous leprosy (CR), 1232

TH17 cells in thalidomide-treated ENL skin biopsies, 626

Taclonex®: FDA approval of Taclonex® topical suspension, 0.005%/0.064% for body plaque psoriasis (PP), 1521

Tangier disease: molecular basis for (RR), 1363

Tazarotene: combination desonide 0.05% and tazarotene 0.05% lichen striatus treatment in children, case series and review (CR), 872

Tea tree oil (TTO) (essential oil of Melaleuca alternifolia): combination TTO and iodine treatment of molluscum contagiosum in children, 349

Tear trough and upper cheek augmentation: two-filler combination injection technique for brighter eyes, 1094

Tear troughs
comparative study of hyaluronic acid injection techniques for treatment of, e80

correction with Emervel® fillers, s27 (January)

Technology. See also Laser technology; Nanotechnology; Radiofrequency technology
melanoma-detecting (Editorial), 1270

Tedizolid: Phase 3 trials (PP), 275

Telangiectasias: multiple lesions: markers for special considerations in diagnosis, therapy, and prognosis, 812

Thalidomide-treated erythema nodosum leprosum: TH17 cytokines in, 626

Thighs: extramedullary plasmacytoma presenting as asymptomatic nodules on buttocks and thighs (RR), 1244

ThioedoxyArbutin (tdA): effects on tyrosinase and melanization, studies, e28

“Three curves of youth”: fillers and (CV), s9 (August)

Thrombotic thrombocytopenic purpura: molecular basis for (RR), 1362

Timolol: topical timolol 0.5% for proliferating infantile hemangiomas, prospective study (CTR), 424

Tinea capitis: treatment options in skin of color, 852

Tinea inguinalis: combination isoconazole nitrate and diflucortolone valerate treatment, retrospective study, e70

Tissue-engineered skin: FDA Orphan Status approval for PermaDerm (PP), 1010

Toenail onychomycosis
distal subungual: Luliconazole Solution 10% safety and efficacy in (CTR), 1013

sub-millisecond Nd:YAG 1,064 nm laser treatment of, 496

Topical steroid allergy (TSA): difficulties in clinically recognizing TSA, and appropriate protocols for diagnosis and treatment, s9 (December)

Tower Technique: novel vertical injection technique for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)

Tri-retinol: anti-aging properties, comparative trial of non-prescription tri-retinol 1.1% vs prescription tretinoin 0.025%, 64

Trabedersen: Orphan Drug designation for malignant melanoma (PP), 1134

Training programs
Duke Dermatology residency training program (RR), 1115

- Georgia Health Sciences University: program spotlight (RR), 240
- Henry Ford Hospital Department of Dermatology Residency Training Program: program spotlight (RR), 1232
- Howard University Hospital Department of Dermatology and Residency Program history (RR), 991
- International Society for Dermatologic Surgery (ISDS), 800
- Mayo Clinic Dermatology Residency Training Program: program spotlight (RR), 104
- National Capital Consortium Dermatology Residency Training Program: program spotlight (RR), 390
- Oregon Health & Science University Department of Dermatology: program spotlight (RR), 653
- San Antonio Uniformed Services Health Education Consortium: program spotlight (RR), 870
- St. Joseph Mercy Health System Dermatology Residency Program (RR), 1497
- training in dermatologic surgery (Editorial), 800
- University of Iowa Hospitals and Clinics (UIHC): program spotlight (RR), 762
- USF Department of Dermatology and Cutaneous Surgery Residency Training Program: program spotlight (RR), 524
- Virginia Commonwealth University Health System Department of Dermatology program (RR), 1356
- Transepidermal water loss (TEWL):** with hydrogel vehicle in atopic dermatitis treatment, 181
- Tretinoin**
- adjunctive SPF 30 moisturizer use with, split-face study, 1104
 - anti-aging properties, comparative trial of non-prescription tri-retinol 1.1% vs prescription tretinoin 0.025%, 64
 - Atralin® gel for penetration of (PP), 130
 - combination clindamycin phosphate 1.2% and BPO 2.5% in the morning and tretinoin 0.05% in the evening acne vulgaris treatment, efficacy and safety study, 748
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% acne rosacea treatment, efficacy and safety study, 333
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% acne vulgaris treatment, efficacy and safety study, 318
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% antimicrobial effects, 1434
 - combination clindamycin phosphate 1.2% and tretinoin 0.025% rosacea treatment: summary of a placebo-controlled, double-blind trial, 1410
 - combination therapy for acne vulgaris, optimizing, 313
 - comparative study of Fla. 855061 5 and tretinoin cream 0.025% for photodamaged skin and acne vulgaris treatments, safety and efficacy study, 737
 - comparative study of skin irritancy from combination clindamycin/tretinoin and benzoyl peroxide/adapalene, 1422
 - prevention of EGFRi-associated dermatologic toxicities study (CTR), 780
 - safety and efficacy of 0.02% cream for facial photodamage, 1036
 - safety and efficacy of 0.02% cream for photodamage reduction, pilot study, 83
- Triax Pharmaceuticals:** acquisition of assets by PreCision Dermatology(PP), 778
- Trichilemmoma:** disease associations (RR), 1237
- Trichloroacetic acid (TCA)**
- combination TCA 50% and cantharidin 0.7% for response to SADBE, 1228
 - comparative study of 80% TCA and 35% TCA wart treatment, e66
- Tricho-dento-osseus syndrome:** skeletal and radiographic findings (RR), 117
- Tricho-rhino-phalangeal syndrome:** skeletal and radiographic findings (RR), 117
- Trichoepithelioma/trichoblastoma:** disease associations (RR), 1237
- Trichofolliculoma:** disease associations (RR), 1237
- Trichoscopy** of cicatricial alopecia, prospective study, 753
- Trichothiodystrophy**
- molecular basis for (RR), 1361
 - skeletal and radiographic findings (RR), 117
- Trimethoprim/sulfamethoxazole:** antiphospholipid antibody syndrome secondary to (CR), 1117
- Triple antibiotic ointment:** nasal *S aureus* clearance with, 1490
- Trius Therapeutics, Inc.:** tedizolid Phase 3 trials (PP), 275
- Tuberculosis**
- giant PPD reaction with positive Quantiferon-TB Gold in a patient with lepromatous leprosy (letter to the editor), 1151
 - TNF- α inhibitor therapy for chronic psoriasis improvement after (CR), 119
- Tuberous sclerosis**
- gene (mode of inheritance) and clinical manifestations (RR), 998
 - histologic characteristics (RR), 1504
 - molecular basis for (RR), 1362
 - skeletal and radiographic findings (RR), 117
- Tumor-infiltrating lymphocytes (TILs),** IL-12 engineered
- metastatic melanoma treatment with, phase I/II study (CTR), 1382
 - metastatic melanoma treatment with, safety and efficacy study (CTR), 1251
- Tumor necrosis factor (TNF) blockers**
- FDA requires follow-up on malignancy cases (PP), 423
 - sarcoidosis as adverse effect of, retrospective case review, 609
- Tumor necrosis factor- α inhibitors**
- chronic psoriasis improvement after *M. tuberculosis* infection treatment with (CR), 119
 - generalized vitiligo treatment with (CR), 534
 - nail psoriasis treatment with TNF- α or IL12/23 inhibitors, review of studies, 939
- Tumor stage acne keloidalis nuchae** treated with surgical excision and secondary intention healing (RR), 540
- Tumor syndrome:** skeletal and radiographic findings (RR), 117
- Tyrosinase:** effects of deoxyArbutin and its derivatives on, studies, e28
- U**
- Ulcers**
- chronic: when to consider malignancy? (NVR), 1006
 - IVIG and methylprednisolone treatment of ulcerated necrobiosis lipoidica (CR), 256
- Ulthera, Inc.:** expansion of operations (PP), 546
- Ultrasound:** comparative study of 1550 nm fractional photothermolysis and intense focused ultrasound treatment of periorbital wrinkles, pilot trial (CTR), 781, 1013
- Ultraviolet B**
- combination alefacept and nbUVB phototherapy for psoriasis, efficacy study, 929
 - effects of topical pimecrolimus 1% on long-term suberythral UVB-irradiated epidermal Langerhans cells, in mice, e25
 - effects on inflammatory processes, co-culture model, 834
- United States**
- international perspective on fillers—from an American perspective, 1089
 - trends in older adult psoriasis outpatient health care practices, 950
- University of Iowa Hospitals and Clinics (UIHC):** program spotlight, 762
- Upper cheek and tear trough augmentation:** two-filler combination injection technique for brighter eyes, 1094
- Upper extremities:** combination blue light ALA-PDT treatment of actinic keratoses on, phase 2 study, 1483
- Upper lip dermabrasion:** new simple, safe, and easy solution for (SC), 649
- Urticaria**
- adrenergic: and rheumatoid arthritis with melanoma (CR), 409
 - after methyl aminolevulinate photodynamic therapy in nevoid basal cell carcinoma syndrome (CR), 1364
- USF Department of Dermatology and Cutaneous Surgery Residency Training Program:** program spotlight (RR), 524
- Ustekinumab (Stelara®)**
- effects on health-related quality of life in Korean and Taiwanese patients with psoriasis, PEARL study results, 943
 - hepatitis B in ustekinumab-treated psoriasis (CR), 1498
 - long-term safety update, 300
 - plaque psoriasis and psoriatic arthritis treatment review, 160
 - plaque psoriasis treatment in a patient with Down syndrome (CR), 998
 - safety in psoriasis, 907
 - severe psoriasis treatment during pregnancy (CR), 1240
- Uveal melanoma, metastatic:** comparative study of sunitinib and dacarbazine treatment of (CTR), 548
- V**
- V-Raser diode laser system:** onychomycosis treatment study (CTR), 1137
- Vaccination,** hepatitis A and influenza: Gianotti-Crosti syndrome associated with (RR), 260
- Vanicream:** combination topical aminocaproic acid and Vanicream rosacea treatment, single-site study, 888
- Vardenafil Hcl:** drug eruption (CR), 1494
- Vascular lesions,** multiple: markers for special considerations in diagnosis, therapy, and prognosis, 812
- Vasculitis,** leukocytoclastic: association with monoclonal gammopathy (RR), 532
- Vemurafenib:** for treatment of metastatic melanoma (NVR), 271
- Verruca vulgaris:** combination TCA 50% and cantharidin 0.7% for response to SADBE, 1228
- Vertical injection:** Tower Technique and Vertical Supraperiosteal Depot Technique: novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)
- Vertical Supraperiosteal Depot Technique:** novel vertical injection technique for volume-efficient subcutaneous tissue support and volumetric augmentation (CV), s45 (August)
- Vichy Laboratories:** introduction of LiftActiv Serum 10 (PP), 1133
- Videography,** digital: assessment of combination adapalene-BPO acne vulgaris treatment patient experiences, 919
- Virginia Commonwealth University Health System Department of Dermatology:** program spotlight (RR), 1356
- Vismodegib (Erivedge™)**
- as adjuvant to surgery for basal cell carcinoma tumors, pilot study (CTR), 1012
 - FDA approves Erivedge (vismodegib) for advanced basal cell carcinoma (PP), 546
 - FDA priority review for new drug application (PP), 131
- Vitamin A deficiency:** skeletal and radiographic findings (RR), 114

Vitamin B5 (dexpanthenol): comparative study of 5% dexpanthenol in water-in-oil and 1% hydrocortisone ointment for childhood atopic dermatitis treatment, 366

Vitamin D supplementation
atopic dermatitis treatment, clinical trial study, 327
evidence for supplement use in atopic dermatitis (NVR), 1245

Vitiligo
anti-TNF- α agent treatment of (CR), 534
combination calcipotriol 0.005% and betamethasone dipropionate 0.05% treatment, efficacy and safety study, e52

Vogt-Koyanagi-Harada disease
in an African-American Female (RR) (CR), 1004
gene (mode of inheritance) and clinical manifestations (RR), 998

Vulvar lesions, erythematous (CR), 110

Vytorin (simvastatin and ezetimibe): alopecia areata treatment, pilot study (CTR), 780

W

Waardenburg syndrome: gene (mode of inheritance) and clinical manifestations (RR), 998

Waldenström macroglobulinemia: association with monoclonal gammopathy (RR), 530

Warts
combination TCA 50% and cantharidin 0.7% for response to SADBE, 1228
comparative study of 80% TCA and 35% TCA treatment, e66

Watson Laboratories, Inc.

FDA approval of Watson's generic Lidoderm (PP), 1249

Lidoderm[®] patent challenge settlement (PP), 887

Watson syndrome: gene (mode of inheritance) and clinical manifestations (RR), 997

Werner syndrome

histologic characteristics (RR), 1503

molecular basis for (RR), 1361

skeletal and radiographic findings (RR), 117

White coat hypertension: in Mohs micrographic surgery, e18

Wilson disease: molecular basis for (RR), 1363

Women: post-adolescent acne in: considerations for, 708

Wrinkle cream claims: FDA warning to Lancome about (PP), 1379

Wrinkles. See also Rhytids

BELOTERO Balance[®] for (PP), 131

Botulinum Toxin Type A Topical Gel treatment of: efficacy and safety study with lateral canthal lines, 38

combination radiofrequency and low-frequency PEMF treatment of, safety and efficacy, 1306

Pellevé[™] treatment of neck wrinkles, prospective study (CTR), 135

X

X-linked ichthyosis: molecular basis for (RR), 1362

Xanthogranuloma, necrobiotic
association with monoclonal gammopathy (RR), 531
of extremities (RR), 122

Xeroderma pigmentosum

gene (mode of inheritance) and clinical manifestations (RR), 997

molecular basis for (RR), 1361

Xoft Axxent Electronic Brachytherapy System: for treatment of NMSC (CTR), 671

Z

Zinc supplementation

effects on botulinum toxin treatments, 507

evidence for supplement use in atopic dermatitis (NVR), 1246